Cover page:  
 
Clinical Trial Protocol : A Phase 2/3, Randomized, Double- Blind, 
Placebo -Controlled,  
Multi -Center Study to Evaluate the Safety and Efficacy of  
TJ003234 in Subjects with Severe Coronavirus Disease 2019 
(COVID-19)  
(Protocol Number TJ003234COV201) 
 
NCT : [STUDY_ID_REMOVED]   
 
Document Date: 23 Sept 2021  
Clinical Trial Protocol  
 
A Phase 2 /3, Randomized, Double -Blind, Placebo -Controlled , 
Multi -Center Study to Evaluate the Safety and Efficacy of 
TJ003234 in Subjects with Severe Coronavirus Disease  2019  
(COVID -19)  
 
 
This study will be conducted according to this protocol, including protocol amendments and in 
compliance with Good Clinical Practice, the ethical principles, and other applicable regulatory 
requirements.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confidentiality  
This document contains confidential information, which should not be copied, referred to, 
released  or published without written approval from I -Mab Biopharma. In the event of any 
actual or suspected breach of this obligation, I -Mab Biopharma must be promptly notified. Protocol number :  TJ003234COV201  
Study drug :  TJ003234  
Indication:  Severe Coronavirus Disease 2019  (COVID -
19) 
Sponsor :  I-Mab Biopharma Co., Ltd.   
Address :  Suite 802, West Tower, 88 Shangke Road  
Pudong New District  
Shanghai  20120, China  
Protocol version  9.0 
Date  23 September  2021  
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  2  
 These restrictions on disclosure will apply equally to all future information supplie d to you that 
is indicated as privileged or confidential.  
 
Sponsor Approval   
 
I have read this protocol and approve it:    
  
Claire (Cong) Xu, MD, PhD  
US Site Head  Date  
  
9/23/2021 | 3:48:32 PM EDT
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  3  
 Sponsor Contact Information  
Name  Title/Role  Contact Information  
Claire Xu , MD, PhD Study Director /Medical 
Monitor  Phone: 317 -755-8242  
Email: claire.xu@i -mabbiopharma.com  
Elizabeth Lindner  Director, Clinical 
Project Management  Phone: 856 -261-4470  
Email:  Elizabeth.lindner@i -
mabbiopharma. us 
Andria White  Clinical Project 
Manager  Phone: 631-356-0091  
Email: Andria. White @i-mabbiopharma. us  
 
If any contact information changes during the course of the study, written notification will be 
provided to the Investigator  and IRB/IEC , per requirements. A  protocol amendment  will not be 
requir ed in this case.  
 
 
 
 
 
 
 
 
 
 
 
 
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  4  
 Investigator Agreement  
I have read the protocol and agree to conduct the study as described herein:  
 
__________________________________________  
Principal Investigator (Printed)   
 
 
    
Principal Investigator (Signature)   Date  
 
  
Clinical Site  
 
By my signature, I agree to personally supervise the conduct of this study at my study site and 
to ensure its conduct is in compliance with the protocol, informed consent, Institutional 
Review Board (IRB)/Ethics Committee (EC) procedures, instructions from I -Mab Biopharma 
representatives, the Declaration of Helsinki, ICH Good Clinical Practices Guidelines, and local 
regulations governing the conduct of clinical studies.  
  
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  5  
 Table of Contents 
 
List of Tables  ................................ ................................ ................................ ...............................  8 
List of Figures  ................................ ................................ ................................ ..............................  8 
Protocol Synopsis  ................................ ................................ ................................ .........................  9 
Schedule of Procedures  ................................ ................................ ................................ ..............  19 
Abbreviations  ................................ ................................ ................................ .............................  21 
1. Background  ................................ ................................ ................................ .....................  25 
1.1. Preclinical Studies  ................................ ................................ ................................ ....... 28 
1.1.1  Toxicological study  ................................ ................................ ................................ .. 28 
1.1.1.1  Tissue -cross Reactivity in Human and Cynomolgus Monkey  ................................ . 29 
1.1.1.2 In vitro Hemolysis Assay  ................................ ................................ ............................  29 
1.1.1.3 Immunotoxicity and immunogenicity  ................................ ................................ ........  29 
1.1.2  Pharmacological Studies  ................................ ................................ ..........................  30 
1.1.2.1 In vitro Pharmacology  ................................ ................................ ..........................  30 
1.1.2.2   In vivo Pharmacology  ................................ ................................ ......................  31 
1.1.3.1  Single -dose Pharmacokinetics  ................................ ................................ .................  35 
1.1.3.2  Repeat -dose Pharmacokinetics ................................ ................................ .............  35 
1.2. Clinical Study  ................................ ................................ ................................ ..............  36 
1.3. Benefits and Risks Assessment  ................................ ................................ ...................  38 
2. Objectives and Endpoints ................................ ................................ ................................  39 
2.1. Objectives  ................................ ................................ ................................ ....................  39 
2.1.1.  Primary Objective  ................................ ................................ ..............................  39 
2.1.2.  Secondary Objectives  ................................ ................................ .........................  39 
2.2. Endpoints  ................................ ................................ ................................ .....................  39 
2.2.1.  Primary Efficacy Endpoint  ................................ ................................ ...............  39 
2.2.2.  Secondary Efficacy Endpoints  ................................ ................................ ..........  39 
2.2.3.  Exploratory Efficacy Endpoints  ................................ ................................ ....... 40 
2.2.4.  Safety Endpoints  ................................ ................................ ................................  40 
3. Investigational Plan  ................................ ................................ ................................ .........  41 
3.1. Study Design  ................................ ................................ ................................ ...............  41 
3.1.1.  Part 1  ................................ ................................ ................................ ........................  41 
3.1.2.  Part 2  ................................ ................................ ................................ ........................  42 
3.1.2.1.  Pharmacokinetic (PK) and Anti -Drug Antibody (ADA) Subgroup  .....................  42 
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  6  
 3.1.3.  Study Populations and Sam ple Size  ................................ ................................ ........  42 
3.2. Scientific Rationale for Study Design  ................................ ................................ .........  42 
3.3. Justification for Dose  ................................ ................................ ................................ ... 44 
3.4. Criteria for Termination of Study  ................................ ................................ ................  45 
4. Selection of Study Populations  ................................ ................................ .......................  45 
4.1. Inclusion Criteria  ................................ ................................ ................................ .........  45 
4.2. Exclusion Criteria  ................................ ................................ ................................ ........  46 
4.3. Subject Numbering  ................................ ................................ ................................ ...... 47 
4.4. Withd rawal Criteria  ................................ ................................ ................................ ..... 47 
5. Study drug  ................................ ................................ ................................ .......................  47 
5.1. Physical and chemical properties, specifications and ingredients of drugs  ................  48 
5.2. Drug Packaging, Labelling, and Storage  ................................ ................................ ..... 48 
5.3. Drug Dispensing, Administration and  Dosage  ................................ ............................  48 
5.3.1.  Randomization and Blinding  ................................ ................................ ............  48 
5.3.1.1.  Part 1  ................................ ................................ ................................ ...................  49 
5.3.1.2.  Part 2  ................................ ................................ ................................ ...................  49 
5.3.2.  Drug Dispensing  ................................ ................................ ................................ . 49 
5.3.3.  Drug Administration  ................................ ................................ ..........................  50 
5.4. Compliance Requirements  ................................ ................................ ..........................  50 
5.4.1.  Contraceptive requirements  ................................ ................................ ..............  50 
5.5. Concomitant Medication and Therapies  ................................ ................................ ...... 50 
5.6. Prohibited Medications  ................................ ................................ ................................  50 
5.7. Rescue Therapies  ................................ ................................ ................................ .........  51 
6. Study Pro cedures ................................ ................................ ................................ .............  51 
6.1. Description of Study Procedures  ................................ ................................ .................  51 
6.1.1.  Vital signs and Pulse Oximetry  ................................ ................................ .........  51 
6.1.2.  Physical examination  ................................ ................................ .........................  52 
6.1.3.  ECG  ................................ ................................ ................................ .....................  52 
6.1.4.  Clinical laboratory tests  ................................ ................................ .....................  52 
6.1.5.  Radiographic Lung Imaging  ................................ ................................ .............  53 
6.1.6.  Pregnancy test  ................................ ................................ ................................ ..... 53 
6.1.7.  Adverse Events (AEs)  ................................ ................................ ........................  54 
6.2. Screening period (Day -3 to Day -1) ................................ ................................ ...........  54 
6.3. Baseline period (Day 1)  ................................ ................................ ...............................  55 
6.4. Follow -up period: Day 2  ................................ ................................ .............................  56 
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  7  
 6.5. Follow -up period: Day 3  ................................ ................................ .............................  56 
6.6. Follow -up period: Day 5  ................................ ................................ .............................  57 
6.7. Follow -up period: Day 7  ................................ ................................ .............................  57 
6.8. Follow -up period: Day 11 ± 1  ................................ ................................ .....................  58 
6.9. Follow -up period: Day 14 ± 2  ................................ ................................ .....................  58 
6.10.  Follow -up period: Day 30± 2 (End of Study Visit)  ................................ .................  59 
6.11.  Discharge from Hospital  ................................ ................................ ..........................  60 
7. Safety and Reporting  ................................ ................................ ................................ ....... 60 
7.1. Adverse Events  ................................ ................................ ................................ ............  60 
7.1.1.  Definition of Adverse Events  ................................ ................................ .............  60 
7.1.2.  Collection of Adverse Events  ................................ ................................ .............  60 
7.1.3.  Criteria for severity of adverse events  ................................ .............................  61 
7.1.4.  Criteria for determining causality between adverse events and study drug  61 
7.1.5.  Follow -up of Adverse Events  ................................ ................................ .............  62 
7.2. Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESI)  ........  62 
7.2.1.  Definition of SAE  ................................ ................................ ...............................  62 
7.2.2.  Adverse Event of Special Interest (AESI)  ................................ ........................  63 
7.2.3.  Reporting of SAEs and AESIs  ................................ ................................ ...........  63 
7.3. Pregnancy  ................................ ................................ ................................ ....................  64 
7.4. Emergency Unblinding  ................................ ................................ ................................  64 
8. Data Handling and Recordkeeping  ................................ ................................ .................  64 
8.1. Data Record and Management  ................................ ................................ ....................  65 
8.2. Protocol Deviations  ................................ ................................ ................................ ..... 65 
8.3. Record Retention  ................................ ................................ ................................ .........  65 
9. Statistic al Considerations  ................................ ................................ ................................  67 
9.1. Sample Size Determination  ................................ ................................ .........................  67 
9.2. General Considerations  ................................ ................................ ...............................  67 
9.3. Subject Demographics/Other Baseline Characteristics  ................................ ...............  68 
9.4. Safety Analysis  ................................ ................................ ................................ ............  68 
9.5. Efficacy Analysis  ................................ ................................ ................................ .........  68 
9.6. Indep endent Data Monitoring Committee  ................................ ................................ ... 69 
10. Regulatory Human Subject Protection and Regulatory Oversight  ................................ . 70 
10.1.  Regulatory and Ethical Considerations ................................ ................................ .... 70 
10.2.  Informed Consent Processes and Documentation  ................................ ...................  70 
10.3.  Confidentiality  ................................ ................................ ................................ .........  71 
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  8  
 10.4.  Conflict of Interest  ................................ ................................ ................................ ... 71 
11. Quality Control and Quality Assurance  ................................ ................................ ..........  73 
12. Confidentiality and Publication of Test Results  ................................ ..............................  73 
13. References  ................................ ................................ ................................ .......................  74 
14. Appendices  ................................ ................................ ................................ ......................  77 
14.1.  Appendix 1: Contraceptive requirements  ................................ ................................  77 
14.2.  Appendix 2: Cardiac Function Grading of NYHA  ................................ ..................  77 
14.3.  Appendix 3: Sequential Organ Failure Assessment Score  ................................ ....... 78 
14.4.  Appendix 4: Inhaled corticosteroid dose guidance  ................................ ..................  79 
 
 List of Tables  
Table 1. Schedule of Procedures  ................................ ................................ ................................  19 
Table 2. Results of in vitro pharmacological studies  ................................ ................................ . 30 
Table 3. TJ003234RAR101: TJ003234 Serum Pharmacokinetic Parameters following Single 
Ascending Intravenous Dose of TJ003234 in Healthy Subjects (PK Population)  ..... 37 
Table 4. Study drug dispensing dose and volume  ................................ ................................ ...... 50 
Table 5. Laboratory Tests  ................................ ................................ ................................ ...........  52 
 
List of Figures  
Figure 1. GM -CSF antibodies inhibited the release of cytokines caused by CAR -T cells.  ..... 26 
Figure 2. Infection of SARS -CoV-2 Caused Hyperactivation of T helper cells to Drive Aberrant 
Monocyte Activation  ................................ ................................ ................................ .. 26 
Figure 3. In vivo Efficacy of Repeat Dose TJ003234 on Type II Collagen Induced Arthritis (CIA) 
Model in Cynomolgus Monkeys  ................................ ................................ ................  32 
Figure 4. Dose respons e relationship of TJ003234 in monkey CIA Model  .............................  33 
Figure 5 : Study Design Schema  ................................ ................................ ...............................  41 
 
  
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  9  
 Protocol  Synopsis  
Protocol Title:  
A Phase 2/3 Randomized, Double -blind , Placebo -Controlled, Multi -Center Study to 
Evaluate the Safety and Efficacy of TJ003234 in Subjects with Severe Coronavirus 
Disease 2019 (COVID -19) 
Objectives:  
Primary Objective:  
To evaluate the effica cy and safety of TJ003234 in subjects with severe COVID -19 with 
supportive care.  
Secondary Objectives:  
 To evaluate the effects of TJ003234 on cytokin es in subjects with severe COVID -
19. 
 To assess the pharmacokinetics  (PK)  and immunogenicity potential of TJ003234 
when administered as a single dose IV infusion in subjects with severe COVID -
19. 
Endpoints:  
Primary Efficacy Endpoints:  
Proportion (%) of subjects who are alive and free of mechanical ventilation at Day 30 
among su bjects who are non-mechanical ventilated at baseline .  
Key Secondary Efficacy Endpoints:  
• Proportion (%) of subjects recovered by Day 14. Recovery is defined as the 
subject scoring a 3, 2, or 1 on the 8 -category ordinal scale below  by Day 14 and 
subsequently does not progress to a score ≥ 4 for the remainder of the study . If a 
subject scores 3 at baseline, this subject is considered to be recovered if this 
subject ’s score improves to 1 or 2 by Day 14. 
8, death; 7, ventilation in addition to extrac orporeal membrane oxygen (ECMO), 
continuous renal replacement therapy (CRRT) or pressors; 6, intubation and mechanical 
ventilation; 5, non -invasive mechanical ventilation (NIV) or high -flow oxygen; 4, 
hospitalization with oxygen by mask or nasal prongs; 3,  hospitalization without oxygen 
supplementation; 2, limitation of activities, discharge from hospital; and 1, no limitation 
of activities, discharge from hospital.  
• Proportion (%) of subjects recovered by Day 30. Sustained recovery is defined 
as the subject  scoring a 3, 2, or 1 on the 8 -category ordinal scale as defined in 
the key secondary  endpoint by Day 30 and subsequently does not progress to a 
score ≥ 4 for the remainder of the study . If a subject scores 3 at baseline, this 
subject is considered to be  recovered if this subject ’s score improves to 1 or 2 by 
Day 30.  
• All-cause mortality rate on Day 30.   
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  10  
 Secondary Efficacy Endpoints:  
• Time to sustained recovery among subjects alive  by Day 30  [Time Frame: Day 
1 through Day 30]: Day of sustained recovery is d efined as the first day on 
which the recovered subject s cores 3,  2 or 1  and maintains such score through 
Day 30 from the 8 -category ordinal scale  as defined in the key secondary  
endpoint. If a subject  is scored at 3 at baseline, day of recovery is defined as the 
day on which this subject ’s score improves to 1 or 2  and maintains such score 
through Day 30 . 
• Length of hospitalization . 
Exploratory Efficacy Endpoints:  
• Improvement in clinical status (Day 7, D ay 14 and Day 30)  
• Sequential Organ Failure Assessment score (SOFA score) (Day 7 and Day 14 
from the day of dosing)  
• Change from baseline in PaO2/ FiO2 (Day 7 and Day 14 from the day of dosing)  
• Length of time to normalization of oxygen saturation which is defined as 
SpO2 ≥94% sustained minimum 24 hours  
• Percentage of subjects requiring mechanical ventilation at Day 7 and Day 14  
• Change from baseline in serum cytokines, e.g. IL -1RA , IL-1β, IL-2, IL -6, IL-7, 
IL-10, GCSF, GM -CSF, CCL2, CCL3, CCL17, CXCL10, TNF -α and IFN -γ, 
etc. (Day 2, Day 3, Day 5, Day 7, and Day 14 from the day of dosing)  
• Change from baseline in D -dimer, cardiac troponin, LDH, and ferritin levels 
(Day 7 and Day 14 from the day of dosing)  
• Peripheral blood neutrophils -to-lymphocyte ratio (NLR)  
Safety Endpoints:  
 Treatment -emergent Adverse events evaluated using the National Cancer 
Institute (NCI)  Common Terminology Criteria for Adverse Events Criteria 
(CTCAE) (version 5.0),  
 Changes from baseline in clinical laboratory parameters, physical examinati ons, 
vital sign measurements,  12-lead electrocardiograms (ECGs), and radiographic 
lung imaging.  
Pharmacokinetic and Immunogenicity  Endpoints:  
• Serum concentration of TJ003234 ( Day 1 predose, Day 1 End of Infusion, Day 
7 and Day 14 ) 
• Incidence and titer of anti-drug antibodies (ADA) (Day 1 predose, Day 14)  
 
Study Design:  
This is a phase 2/3  randomized, double -blind , placebo -controlled, multi -center  trial to 
evaluate the safety and efficacy of TJ003234 administered as an intravenous  (IV) 
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  11  
 infusion in subjects with severe COVID -19 under supportive  care, and to assess the 
effect of TJ003234 on the levels of cytokines.  The study will be conducted in two parts.  
Part 1 : 
Part 1 is designed as a randomized, double -blind, placebo -controlled, 3 -arm, parallel -
group study to evaluate the safety of TJ003234 in subjects with severe COVID -19. 
Potential subjects will be screened to assess their eligibility to enter the study within 3 
days prior to study drug administration. A total of 24 eligible subjects  will be randomized 
at a ratio of 1:1:1 to receive either a single dose of 3 mg/kg TJ003234, a single dose of 
6 mg/kg TJ00324 or placebo, administered by IV infusion. Before and after the 
treatment, all subjects will be allowed to receive supportive care a nd/or additional 
treatments for COVID -19 and its complications per the Investigator. Up to twenty -four 
subjects will be enrolled in Part 1.  If no more than 2 out of 8 subject s experience a Grade 
≥3 treatment -related adverse event ( AE) within 7 days of the subjects receiving the study 
drug in either TJ003234 arm and no more than 4 out of 16 subjects experience a Grade 
≥3 treatment -related AE within 7 days of the subjects receiving the study drug in both 
TJ003234 arms combined, Part 2 wi ll be initiated.  The end of Part 1 is defined as 30 
days after the last subject is dosed , or until study termination.   
Part 2 : 
Part 2 is designed as a randomized, double -blind, placebo -controlled, 2-arm, parallel -
group study to evaluate the safety and effi cacy of TJ003234 in subjects with severe 
COVID -19. Part 2 contains two phases, the first phase, Phase 2, will enroll 1 20 subjects 
and the second phase, Phase 3, will enroll approximately 450 subjects. The data collected 
from Phase 2 will be used to make de cision for Phase 3 and may be used to re -estimate 
sample size of Phase 3 portion. Potential subjects will be screened to assess their 
eligibility to enter the study within 3 days prior to the first dose administration. A total 
of 570 eligible subjects will  be randomized at a ratio of 2:1 to receive either a single 
dose of TJ003234 or placebo, administered by intravenous infusion.  Subjects in Part 2 
Phase 2 will receive either a single dose of  6 mg/kg TJ003234 or place bo. Subjects in 
Part 2 Phase 3 will rece ive either a single dose of 10 mg/kg TJ003234 or placebo.  
Randomization will be stratified by age and use of remdesivir . Before and after the 
treatment, all subjects will be allowed to receive supportive care and/or additional 
treatments for COVID -19 and its complications per the Investigator.   
Follow -up Period : 
After study drug administration, all subjects will enter a follow -up period and will be 
evaluated for safety and efficacy  for 30 days after the last dose of study drug. Subjects 
will be followed for 30 days following the day of dosing (Day 1), or until withdrawal 
of consent, lost to follow -up, or death.  
End of study is defined as Day 30 from the day of enrollment of the last subject, or 
study termination.  
Safety Evaluations:  
All adverse events wil l be collected from the day of informed consent to Day 30.  
All subjects who received the study drug will be included in the safety analysis. The 
CTCAE Version 5.0  will be used as the criteria for safety evaluation.  
The safety evaluation s will be performed at Screening, Day 1 predose ( baseline), Day 7, 
Day 14 and Day 30.  
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  12  
 Safety endpoints will include treatment -emergent adverse events, changes from baseline 
in physical examinations, clinical laboratory parameters, vital sign measurements, pulse 
oximetry, 12 -Lead ECG, and  radiographic  lung imaging.  
Clinical laboratory parameters will include complete blood count (CBC), serum 
chemistry (including Lactate Dehydrogenase  (LDH) ), coagulation profile, troponin, 
arterial blood gas analysis, C -react ive Protein (CRP), and Severe Acute Respiratory 
Syndrome Coronavirus 2  (SAR S-CoV-2) diagnostic test  by polymerase chain reaction 
(PCR) or other commercial or public health assay . 
Radiographic lung imaging will include lung computed tomography ( CT) or lung X-ray. 
Efficacy Evaluations:  
The efficacy evaluations in this study will be performed based on clinical status ( 8-
category ordinal scale), sequential organ failure assessment (SOFA) score, and PaO2/ 
FiO2. They will be evaluated from Day 1 predose (baseline)  to Day 30 . In addition, the 
subjects will be assessed for all -cause mortality and need for mechanical ventilation.  
Changes from baseline in serum cytokines including IL -1RA , IL-1β, IL-2, IL -6, IL-7, 
IL-10, GCSF, GM -CSF, CCL2, CCL3, CCL17 , CXCL10 , TNF -α and IFN-γ, etc.  will 
be measured on Day 1 pre -dose, and Days  2, 3, 5, 7, and 14 post -dose.  
Sample Size:  
This is a 2 -part study. Part 1 will enroll about 24 subjects to establish the safety profile 
of single dose of  3 mg/kg and 6 mg/kg of TJ003234 in subjects with severe COVID -19 
before moving to Part 2.  Part 2 plans to enroll  570 subjects. Eligible s ubjects will be 
randomized  to TJ003234 or placebo with a ratio  of 2:1. Assuming mechanical ventilation 
free rates by Day 30 are 77% in the control arm and 88% in the treatment arm, with 10% 
drop-out rate, a total of  120 subject s are required based on a 2 -sided alpha level of 0.2 
and 80% power  in the Phase 2 portion , and a total of 450 subjects are required based on 
a 2-sided alpha level of 5% and 80% power in the Phase 3 portion . 
Scientific Rationale for Study Design : 
GM-CSF, as a key upstream trigger factor in the inflammatory cytokine cascade, can 
enhance the effects of neutrophils and macrophages, produce inflammatory cytokines  
and activate the phagocytosis. In addition, GM -CSF is also an important cytokine that 
induces the polarization of monocytes to the inflammatory M1 phenotype and promotes 
the activation of macrophages, and the macrophages secrete a large number of 
inflamma tory cytokines such as IL -6 and TNF -α, to involve in tissue inflammation  
(Hamilton,  1980 ). The strong proinflammatory effects of GM -CSF make it a promising  
target in acute inflammatory conditions where elevated GM -CSF has been implicated in 
orchestrating a cytokine storm. At least three such syndromes share immunological and 
pathologic features of a cytokine storm: chimeric antigen receptor (CAR) -T cell ther apy 
related cytokine release syndrome (CRS), macrophage activation syndrome (MAS) and 
most recently, acute respiratory distress syndrome (ARDS) in severe coronavirus disease 
(COVID -19) cases caused by SARS -CoV-2 (severe acute respiratory syndrome 
coronavir us 2).  
In the recent COVID -19 epidemic caused by the coronavirus SARS -CoV-2 in China, 
approximately 15-30% of severe  COVID -19 patients developed ARDS  (Wang , 2020 ; 
Huang, 2020 ; Chen, 2020 ; Guan, 2020 ). Without intervention, the clinical course is 
expected to be dire for severe COVID -19 patients. Therefore, there is a huge unmet 
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  13  
 medical need of  therapy for severe COVID -19 patients. At present, there is no specific 
immune modulating therapy for severe COVID -19 patient.  
The clinical features ( Huang, 2020 ) and immunopathology ( Xu, 2020 ) of patients with 
COVID -19 in China have now been reported,  and they remarkably resembled those 
found in SARS ( Channappanavar, 2017 ). Common features among COVID -19 patients, 
particularly those seriously or critically ill, included lymphopenia and significantly 
elevated  levels  of inflammatory cytokines including IL-1, IL-7, IL -8, IL -9, IL -10, basic 
FGF, G -CSF, GM -CSF, IFN -γ, IP-10, MCP -1, MIP -1A, MIP -1B, PDGF, TNF -α, and 
VEGF . (Huang, 2020 ). Massive production of IL -6, CRP, D -dimer and ferritin  were  also 
observed , which are  all indicative of  cytokine storm ( Wang, 2020 ). Importantly, lung 
pathology revealed heavy interstitial lymphocytic infiltrates along with diffuse alveolar 
damage with fibromyxoid  exudates, multinucleated giant cells and hyaline membrane 
formation, indicative of ARDS ( Xu, 2020 ). Interestingly, these pathological features and 
lung CT imaging characteristics are also remarkably similar to those reported for a subset 
of Systemic Juvenile Idiopathic Arthritis (JIA) patients that developed MAS that led to 
severe immunopathology and lung disease ( Schulert, 2019 ).  
It seems evident  from the recent reports that severe COVID -19 bears all the hallmarks 
of a cytokine storm instigated by exuberant immune cells producing GM -CSF and IL -6. 
They drive aberrant monocyte and T cell activation which in turn produce more 
cytokines and chemokines in a feed forward cycle that culminates in profound  tissue 
injury, airway constriction, vascular collapse and organ failure ( Zhou, 2020 ). Peripheral 
blood mononuclear cell ( PBMC ) immunophenotyping showed an abundance of highly 
active GM -CSF-producing T helper cells and pathogeni c monocytes in COVID -19 
patients ( Xu, 2020 ; Zhou, 2020 ). A recent study published in Blood showed that GM -
CSF antibodies have been demonstrated to effectively inhibit the cytokine storm caused 
by CAR -T cell therapy and reduce the levels of a series of inflammatory factors such as 
IFN-g, IL -6, MCP -1, MIP -1 in preclinical experiments. In addition, it can control the 
infiltration of immune cells such as T cells and macrophages into the central nervous 
syste m, and effectively inhibit the generation of neurotoxicity  (Sterner et al., 2019 ). 
Compared to tocilizumab that has been widely used to treat cytokine storm caused by 
CAR -T cells, GM -CSF antibodies may have  better efficacy , especially in regulating the 
broad spectrum of cytokines and inhibiting neurotoxicity. Therefore, two clinical trials 
will be conducted to evaluate the therapeutic effects of GM -CSF antibodies or GM -CSF 
receptor antibodies on CAR -T cell -induced side effects  such as cytokine storm and 
neurotoxicity  (Gilead, 2020 ). Currently, based on the experience of IL -6R antibody 
tocilizumab in managing CAR -T induced CRS, tocilizumab is being tested for reducing 
cytokine storm and its complica tions in a clinical trial of COVID -19 patients in China  
(Chinese Clinical Trial Registry, n.d.) . GM-CSF neutralizing antibody such as TJ003234 
may also  have the potential to  prevent or curb cytokine storm and  immunopathology and 
thus earn more time for viral clearance , which may improve the overall clinical outcome 
of COVID -19 severe patients .  
 
Justification for Dose: 
In this study, the dose of TJ003234 has been predicted based on the results of safety, 
pharmacokinetics and pharmacodynamics from a single ascending dose study in healthy 
subjects, preclinical data, the safety data of similar GM -CSF antibodies in patients with 
rheumatoid arthritis, as well as the data of IL -6R antibody tocilizumab for treatm ent of 
cytokine storms . For TJ003234, a single dose escalation study in 32 healthy subjects has 
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  14  
 been completed. No dose limiting toxicity (DLT) was observed in the 0.3 mg/kg, 1 
mg/kg, 3 mg/kg and 10 mg/kg dose groups. The maximum tolerated dose (MTD) was 
not reached. The half -life of TJ003234 was approximately 3 weeks and plasma 
concentrations increased proportionally with the dose over the range 0.3 mg/kg to 10 
mg/kg. Pharmacodynamics showed similar levels of inhibition of ex -vivo GM -CSF-
activated phosphor ylated signal transducer and activator of transcription 5  (pSTAT5 ) at 
doses of TJ003234 3 mg/kg and 10 mg/kg. Inhibition of more than 90% was reached at 
4 hours after dosing and was maintained for 2 weeks  (full clinical study report  submitted 
to FDA in Jan uary 2020 ).  
The dosing regimen of TJ003234 in the Part 2 Phase 3 trial is amended as 10 mg/kg 
TJ003234 or placebo based on the observed efficacy, safety, and PK data in the 
completed Part 2 Phase 2 study. In Part 2 Phase 2 study  with patients with Covid -19, 
improved efficacy over the placebo arm was observed with an acceptable toxicity profile  
of TJ003234 . At the same time, increased clearance of TJ003234 (0.02 L/hr in patients 
with Covid -19 compared to 0.009  L/hr i n healthy subjects)  was observed at a single dose 
of 6 mg/kg TJ003234 , with a shorter half -life (6 days)  than in healthy subjects  (3 weeks).  
Therefore, a  single dose of 10 mg/kg  is expected to  further improve the magnitude of 
efficacy  improvement by providing higher exposure  than that of 6 mg/kg dose in Covid -
19 patients . Based on the observed PK data, the exposure of a single dose of 10 mg/kg 
TJ003234 in patients with Covid -19 is expected to be lower than that in healthy subjects. 
Therefore,  an acceptable safety profile  is expected to  be maintained , as the 10 mg/kg has 
been tested in healthy subjects with excellent safety profile.  According to the preclinical 
toxicology study ( once weekly ( Q1W) for 4 weeks), the No -Observed -Adverse -Effect 
Level (NOAEL) dose in Cynomolgus monkeys was 60 mg/kg. Since molecular weight 
of TJ003234 is >100 ,000 Da (146KDa)  and administered intravenously, according to 
FDA guidance  stating that proteins administered int ravascularly with molecular 
weight >100 KDa should be normalized to mg/kg as an exception to mg/m2 scaling 
approach  (CDER, 2005 ), the calculated Human equivalent dose (HED) based on 
NOAEL is also 60 mg/kg.   
GM-CSF antibod ies have been reported to be well tolerated in clinical trials. Namilumab 
and KB003 are drugs with the same mechanism of action as the study drug and both 
were well tolerated at doses of 5 -6 mg/kg  (Huizinga et al., 2017 ). The Phase IIb clinical 
trial of mavrilimumab, which is an antibody of GM -CSF receptor and has a similar 
mechanism of action as the study drug, showed no adverse reactions in the lung  
(Burmester et al., 2017 ). The autoantibodies of GM -CSF are associated with the 
development of idiopathic autoimmune pulmonary alveolar proteinosis (PAP). There is 
a theoretical risk of developing PAP when therapeutic antibodies targeting GM -CSF are 
used. Non-clinical studies of m avrilimumab, a compound targeting GM -CSF receptor , 
showed  that macrophage change in lung tissues was only observed in studies with dosing 
lasting more than 11 weeks  (Ryan  et al. , 2014 ). Therefore, i t is believed that PAP is a 
long-term chronic development process  and, the risk of PAP developed from drug 
exposure after a single dose is most likely to be low. In addition, we closely monitored 
pulmonary function up to 90 days and no clinical ly meaningful changes of pulmonary 
functio n were observed in the single dose escalation study  (full clinical study report 
submitted to FDA in January 2020 ). Taken together with the safety data in human and 
preclinical studies, we believe that a single dose of 3 mg/kg and 6 mg/kg  TJ003234 will 
be safe in the patient population.  
Preclinical pharmacodynamics showed a treatment effect of <50% (as measured by an 
inhibitory effect on the GM -CSF/GM -CSFR signaling pathway) at a single intravenous 
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  15  
 infusion dose of 3 mg/kg in the CIA (type II collagen -induc ed arthritis) model in 
cynomolgus monkeys. The results from the in vitro monocyte activation assay to mimic 
the COVID -19 viral stimulation of primary monocytes confirmed that treatment of 10 
μg/ml TJ003234 suppressed the pro -inflammatory cytokine productio n and activation 
marker expression, indicating that the dose of 3 mg/kg may be efficacious since the 
trough concentration of a single dose of 3 mg/kg exceeds 10 µg/ml in the Phase I clinical 
trial. On theoretical grounds, the GM -CSF levels will further inc rease in COVID -19 
patients with cytokine storms compared to healthy individuals and patients with 
autoimmune diseases. This hypothesis has been confirmed  by the clinical data of 
tocilizumab. The mean peak concentration of tocilizumab in patients with cytok ine 
storms caused by CAR -T was 41% lower than that in patients with systemic JIA, 
suggesting that tocilizumab was eliminated more rapidly in patients with cytokine 
storms (Le et al., 2018 ). Therefore, in order to better assess the  dose response of 
TJ003234 in COVID -19 severe patients, and determine an optimal dose for further 
development, we plan to include an additional dose level of 6 mg/kg TJ003234. Based 
on the PK from healthy adults, TJ003234 PK appears to be linear and we exp ect that a 
single dose of 6mg/kg may produce two -fold of drug exposure following a single dose 
of 3 mg/kg TJ003234, which will remain within the range of drug exposure tested to be 
safe in the first-in-human ( FIH).   
Overall, the totality of the data from the non -clinical data and clinical data from the 
single ascending dose escalation study supports 3 mg/kg  and 6 mg/kg  as a safe dose 
with potential efficacy to be administered in COVID -19 patients. Furthermore , the 
observed efficacy, safety, and PK data in the completed Part 2 Phase 2 study  support a 
single dose of 10 mg/kg TJ003234 in the subsequent Part 2 Phase 3 trial  as a safe dose 
with further improved efficacy .  
Inclusion and exclusion criteria:  
Inclusion criteria (To be included in the study, subjects must meet all of the 
following criteria):  
1. Age: 18 years or older (including 18 years); male or female  
2. Laboratory -confirmed SARS -CoV-2 or COVID -19 infection  as determined by 
polymerase chain reaction (PCR) or other commercial or public health assay.  
3. Bilateral lung infection confirmed by imaging . 
4. Severe disease that meets one of the following conditions:  
i. At rest, finger blood oxygen saturation ≤ 93% or PaO2/FiO2  ≤ 300 
mmHg; OR  
ii. Requiring high flow oxygen ≥15L/min  
 
5. Subjects or legally authorized representatives (LARs) who are willing to 
participate in this study and sign the informed consent voluntarily.  
6. Be willing to follow the contraception guid elines in Appendix 1  
7. Subject has been hospitalized for no more than 5 calendar days at the time of 
screening.  
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  16  
 Exclusion Criteria (Subjects who meet any of the following criteria will be excluded 
from the study):  
1. Any previous and/or current clinically significant disease or condition that has not 
been stable within 3 months prior to enrollment, or acute illness, planned medical/ 
surgical procedure, or any trauma that occurred within 2 weeks prior to enrollment, 
which, in the opinion of the investigator,  may place the subject at risk if participating 
in the study, or may interfere with the assessment of the study drug or confound 
interpretation of the study results, or affect the patient's ability to participate in the 
study independently.  
2. Applies to Part 1 Only: Chronic obstructive pulmonary disease (COPD) and 
moderate/severe asthmatic patients requiring inhaled corticosteroid, long -acting 
beta-adrenergic agonists, long -acting anticholinergics, or long -term oxygen therapy. 
Mild asthmatic pa tients treated with short -acting beta -adrenergic agonists and/or low 
dose of inhaled corticosteroid and/or long -acting beta -adrenergic agonists are 
considered eligible. Please refer to Appendix 4 for inhaled cortiscoteroids dose 
guidance.  
3. Pulmonary interst itial disease, pulmonary alveolar proteinosis, and pulmonary 
granulomatosis.  
4. Cardiovascular event in the 3 months prior to study drug administration: acute 
myocardial infarction or unstable angina pectoris, severe arrhythmia (multiple 
sources of frequent v entricular premature beat, ventricular tachycardia and 
ventricular fibrillation); New York Heart Association Classification (NYHA): Class 
III-Class IV.  
5. Severe renal impairment: e.g. eGFR ≤30 ml/min estimated by MDRD equation  or 
have received treatments suc h as kidney transplantation and dialysis.  
6. Subjects that cannot adhere to protocol requirements due to neuropsychiatric 
disorders.  
7. Severe liver disease: e.g. Child -Pugh Score for Cirrhosis as Grade C, elevated 
aspartate aminotransferase (AST) or alanine ami notransferase (ALT) > 5 × upper 
limit of normal.  
8. Known active or chronic hepatitis B or C infection or human immunodeficiency 
virus (HIV).  
9. Known active tuberculosis (TB), history of incompletely treated TB, suspected or 
known extrapulmonary TB, suspected o r known systemic bacterial or fungal 
infections.  
10. Blood system disorders or routine blood analysis test abnormalities:  
 Hemoglobin < 8 g/dL;  
 Absolute neutrophil count ( ANC ) <1500 × 109/L; 
 Platelets < 50 × 109/L. 
11. Dependence on glucocorticoid treatment equivalent to methylprednisolone 2 mg/kg/ 
day or more or long -term use of anti -rejection or immunomodulatory drugs.  
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  17  
 12. Subjects that require invasive mechanical ventilation or ECMO.  
13. Pregnant or breastfeeding females.  
14. Have received any live vaccination within 30 days before dosing.  
15. Subjects who, in the opinion of the investigator, are not suitable for participation in 
this clinical study  or will not agree to follow the institution ’s supportive care  
protocol . Any condition that, in the opinion of the investigator, may increase the risk 
associated with the subject's participation in the study or may interfere with the 
assessment of the study drug or confound the interpretation of the study results.  
 
Criteria for study termination  
During the conduct of the study, if the investigator or the sponsor finds that continuation 
of the trial may cause potential harm to subjects, the decision may be made to terminate 
the trial after consultation between the investigator, medical monitor and the sponsor.  
Statistical Considerations:  
Analysis Populations:  
Intent -to-treat (ITT) Population: All randomized subjects . This population will be used 
for the  primary analysis for Part 1 and Part 2 phase 2 portion, and sensitivity analysis of  
primary  analysis  for Part 2 phase 3 portion . 
Modified Intent -to-treat (mITT) Population: All randomized subjects  who are non-
mechanical ventilat ed at baseline . This population will be used for the primary analysis  
for Part 2 phase 3 portion . 
Safety Population : Includes all subjects who receive  the study drug. This safety 
population will be used for the analysis of demographic data, baseline characteristics, 
and safety.  
Efficacy -evaluable Population: All subjects in the safety population with at least one 
post-dose efficacy evaluation.  
General M ethods : 
All data will be summarized by treatment group using descriptive statistics based on the 
data types. Unless otherwise specified, descriptive statistics for continuous variables will 
include number of subjects, mean, standard deviation (SD), median, and range . For 
categorical variables, descriptive statistics including counts and percentages will be 
report ed. Data from Part 1 and Part 2 will be analyzed separately .  
Safety Analysis:  
Safety and tolerability evaluations will be performed for all subjects in the safety 
population . 
AEs will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA). Summary statistics and listings of all the safety data will be provided by 
treatment group  and time points as specified in the schedule of procedures.  
Efficacy Analysis:  
For each part, efficacy endpoints will be summarized by treatment group with 
Version 9.0   Version Date: 23 September  2021  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  18  
 descriptive statistics based on the ITT / mITT / efficacy -evaluable population . Treatment 
difference along with the 95%  CI will be reported . Subgroup analysis by  age at 
randomization  (<60  years , ≥60 years ) and use of remdesivir (yes /no) might be performed 
where data permits.  
For the efficacy endpoint s in Part 2, the primary endpoint will be analyzed using the 
exact method. Difference between two arms will be tested by a stratified Cochran –
Mantel –Haenszel test (CMH) test  using  the stratification factors at randomization .  
Recovery rates by Day 14, recovery rate s by Day 30 , and all-cause mortality rate,  will 
be analyzed similarly. Time to recovery among subjects alive by Day 30 will be analyzed  
by a stratified log -rank test  for p -value , and the HR ratio between two arms will be 
estimated by a stratified Cox proportional hazard model  using the stratification factors 
at randomization . 
For the Phase 3 portion,  multiplicity will be adjusted by a gatekeep ing procedure . If 
the null hypothesis  for the primary endpoint is rejected , then t he key secondary endpoints 
will be tested in the order of:  recovery rate by Day 14 , recovery rate  by Day 30, and all-
cause mortality rate  by Day 30 .  
 
The trial will be considered as successful if the primary endpoint in Phase 3 portion 
shows a statistically significant improvement in the treatment arm and , as a safety 
measurement, the  all-cause mortality rate in the treatment arm is numeri cally not high er 
than that in the control arm.  
Independent Data Monitoring Committee  (IDMC ):  
The IDMC  is responsible for monitoring safety . The IDMC  will be made up entirely of 
members external to I-Mab. The IDMC  charter will contain membership information 
and a further delineation of responsibilities.  
The IDMC  may recommend continuing  enrollment in one dose arm or to terminate the 
study for accumulated safety evaluations . The IDMC  will provide a recommendation 
that is made without known bias. I -Mab staff involved in the conduct of the study will 
be kept blinded before a portion of the study is completed , and the members of the IDMC  
will not have involvement with the conduct of the study . 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  19  
 Schedule of Procedures   
Table 1. Schedule of Procedures    
Procedure  Screening 
period * Baseline 
period * Follow -up period  
-D3-D1 D1 D2 D3 D5 D7** D11** 
±1 D14** 
±2 D30**
±2 
Informed Consent  √         
Demographics  √         
Body weight  √         
Medical history, smoking 
history and medication history , 
and baseline respiratory support 
requirements  √ √        
Pregnancy test or FSH test [1] √         
SARS -CoV-2 diagnos tic test [2] √     (√)  (√) (√) 
Radiographic l ung imaging [3] √ √    √  √ √ 
Arterial blood gas analysis [4, 16] √ √    √  √ √ 
PaO2/FiO2[16] √ √    √  √ √ 
Physical Exam ination  √ √ √ √ √ √  √ √ 
Pulse Oximetry  [5] √ 
Clinical status [6]  √    √  √ √ 
Vital signs  √ √ √ √ √ √ √ √ √ 
12-lead ECG [7] √ √    √  √ √ 
Routine complete blood  count , 
blood biochemistry test , 
coagulation assessment [8] √ √ √ √ √ √  √ √ 
Urinalysis  [9] √ √ √ √ √ √  √ √ 
Troponin   √    √  √  
C-reactive protein , LDH, serum 
ferritin  √ √ √ √ √ √  √ √ 
Cytokine levels [10] √ √ √ √ √ √  √ √ 
SOFA (Sequential Organ Failure 
Assessment score) [11, 16]  √    √  √ √ 
Review subject eligibility  √ √        
Randomization   √        
Dosing [12]   √        
Pharmacokinetic Sampling [13]  √    √  √ √ 
Anti-drug Antibody Sampling  
[14]  √      √ √ 
Concomitant 
medication/treatment [15]  √ 
Adverse events  √ 
 
[1] Pregnancy test is required for women of childbearing potential and follicle stimulating hormone ( FSH) is required if 
confirmation of postmenopausal status is needed.  
[2] SARS -CoV-2 diagnos tic test by polymerase chain reaction (PCR) or other commercial or public health assay : If a 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  20  
 subject has a positi ve test within the 14 days prior to study drug administration , an additional test at screening does 
not need to be performed. Tests during follow -up are requested, but if missed or done out of window, this will not be 
considered a protocol deviation .  
[3] Radi ographic l ung imaging examination : Including lung CT or chest X -ray. If this procedure was performed as 
standard of care in the 14 days prior to study drug administration  and radiographic infiltrates  are present , this may be 
used,  and imaging is not required at Screening or Day 1.    
[4] Arterial blood gas analysis , finger blood oxygen saturation : arterial blood gas analysis : PH, partial pressure of oxygen, 
partial pressure of carbon dioxide, total carbon dioxide, oxygen saturation, actual bicarbonate, standard bicarbonate, 
base excess , anion gap. If the interval between arterial blood gas analysis  performed during screening an d dosing  is 
less than 24 hours , a repeated test is not required on Day 1 predose . If Day 7 and/or 14 visits are conducted as 
outpatient visits, it is not necessary to perform an this procedure . 
[5] Pulse oximetry should be recorded on a daily basis while the subject  is hospitalized.  The lowest registered level from 
each day should be recorded.  
[6] Clinical status  evaluation:  8-category ordinal scale score: 8, Death; 7, ventilation in addition to ECMO, CRRT or 
pressors; 6, Intubation and mechanical ventilation; 5, NIV or high -flow oxygen; 4,  Hospitalization with oxygen  by 
mask or nasal prongs; 3, Hospitalization without oxygen supplementation; 2, Limitation of activities , discharge from 
the hospital ; and 1, No limitation of activities, discharge from hospital.    
[7] ECG : Including but not limited to heart rate, QT, QTc, QTcF and P -R interval.  
[8] Routine CBC : White blood cells, red blood cells, hemoglobin, hematocrit, mean cell volume, platelets, absolute 
neutrophil count  and percentage, absolute lymphocyte  count  and percentage, absolute monocyte  count  and percentage , 
absolute eosinophil  count and percentage, absolute basophil count and percentage . Blood biochemistry test: blood 
glucose; liver and kidney function s: alanine aminotransferase  (ALT), aspartate aminotransfe rase (AST), total protein , 
albumin, total bilirubin, direct bilirubin, alkaline phosphatase (ALP), γ-glutamyltransferase (GGT), creatinine, blood 
urea nitrogen (BUN) , uric acid; serum electrolytes: potassium, sodium, chlorine, calcium, magnesium, inorganic 
phosphorus. Coagulation function: prothrombin time (PT), activated partial thromboplastin time ( aPTT), international 
normalized ratio (INR), D -dimer.  For screening, labs drawn before informed consent may be used if th ey are collected 
within 72 hours of study drug administration. Please see Section 6.2 for details.  
[9] Dipstick is acceptable. Microscopic analyses if dipstick abnormal.  
[10] Cytokines  such as  IL-1RA, IL -1β, IL-2, IL -6, IL -7, IL -10, GCSF, GM -CSF, CCL2, CCL3, CCL17 , CXCL10, TNF -
α and IFN -γ in serum.  
[11] SOFA  (Sequential Organ Failure Assessment score ): see Appendix 3.  
[12] Dosing: intravenous infusion. On Day 1, all corresponding assessments will be completed before dosing.   
[13] Only applies to subjects in Part 2 randomized to the PK/ADA subgroup. Pharmacokinetic Samples will be collected 
on Day 1 predose, Day 1 end of infusion (± 15 minutes), Day 7 , Day 14 , and Day 30 . The Day 30 sample only must 
be collected if the subject is sti ll hospitalized or is able to come in for an outpatient blood draw.  
[14] Only applies to subjects in Part 2 randomized to the PK/ADA subgroup.  The Day 30 sample only must be collected 
if the subject is still hospitalized or is able to come in for an outpatient blood draw.  
[15] Recording concomitant medication/treatment: The concomitant medication mainly includes antiviral drugs, 
antibiotics, Glucocorticoid, and circulatory support drugs. Concomitant treatment mainly includes oxygen therapy, 
non-invasive/invasive mechanical ventilation, ECMO, and continuous renal replacement therapy (CRRT).  Any 
SARS -CoV-2 vaccine history  will be collected. For subjects who report they have received the SARS -CoV-2 vaccine,  
the following will be collected: Number of doses, date of do se(s) and brand name.  
[16] If subject is discharged from the hospital during the study , complete an unscheduled  SOFA score , ABG  and 
PaO2/FiO2 ratio  based on the last arterial blood gas analysis performed while the subject was hospitalized . 
*If dosing occurs  within 24 hours of screening, any Predose procedures done during screening  do not need 
to be repeated. SOFA, troponin, clinical status assessment  must be collected prior to dosing.  Please see 
Section 6 for details.  
**If subject is discharged prior to these visits, they may occur as outpatient or telephone visits . Please see 
Section 6 for details.  
  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  21  
 Abbreviations  
ANC  Absolute neutrophil count  
AE Adverse Event  
ARDS  Acute Respiratory Distress Syndrome  
ADCC  Antibody -dependent cell -mediated cytotoxicity  
AB Actual bicarbonate  
AESI  Adverse Event of Special Interest, AESI  
AG Anion gap  
AUC  Area Under the Curve  
APTT  Activated partial throm boplastin time  
ADA  Anti-Drug Antibody  
AST  Aspartate aminotransferase  
ALT alanine aminotransferase  
ALP  Alkaline phosphatase  
CIA Collagen -Induced Arthritis  
CRP  C-Reactive Protein  
CL Clearance  
CSF2  Colony -Stimulating Factor 2  
CAR -T Chimeri c antigen receptor  
CRF  Case report form  
CTCAE  Common Terminology Criteria for Adverse Events  
Cmax Maximum  concentration  
CBC  Complete blood count  
CFR  Code of Federal Regulations  
CDC  complement dependent cytotoxicity  
CRP  C-Reactive Protein  
CT Computed Tomography  
COVID -19 Coronavirus Disease 2019  
CRS  Cytokine Release Syndrome  
CRRT  Continuous renal replacement therapy  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  22  
 CI Confidence Interval  
CIOMS  Council for International Organizations of Medical 
Sciences  
CRO  Clinical Research Organization  
COPD  Chronic obstructive pulmonary disease  
DLT Dose -Limiting Toxicity  
ECG  Electrocardiogram  
eGFR  Estimated glomerular filtration rate  
EOI End of Infusion  
EC Ethic Committee  
ECMO  Extracorporeal membrane oxygenation  
FDA  Food and Drug Administration  
FIH First-in-human  
FSH Follicle Stimulating Hormone  
GGT  Gamma -glutamyltransferase  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
GM-CSF Granulocyte -Macrophage Colony -Stimulating Factor  
HIV Human Immunodeficiency  Virus  
HED  Human Equivalent Dose  
ICH International Committee on Harmonization  
IDMC  Independent Data Monitoring Committee  
IRR Infusion Related Reaction  
IND Investigational New Drug  
IRB Institutional Review Board  
IV Intravenous  
INR International normali zed ratio  
JIA Juvenile Idiopathic Arthritis  
LAR  Legally Authorized Representative  
LDH  Lactate Dehydrogenase   
MAS  Macrophage Activation Syndrome  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  23  
 MedDRA Medical Dictionary for Regulatory Activities   
MTD  Maximum Tolerated Dose  
MAD  Maximum Administered Dose  
NIV Non-Invasive Mechanical Ventilation  
NCI National Cancer Institute  
NLR  Neutrophil to lymphocyte ratio  
NYHA  New York Heart Association  
NOAEL  No Observed Adverse Effect Level  
PBMC  Peripheral Blood Mononuclear Cell  
PAP Pulmonary Alveolar Proteinosis  
PD Pharmacodynamics  
PIP Proximal Interphalangeal Joint  
pSTAT5  Phosphorylated Signal transducer and activator of 
transcription 5  
PK Pharmacokinetics  
PaO2  Partial Pressure of Oxygen  
PT Prothombin time  
PCR  Polymerase chain reaction  
Q1W  Once weekly  
RTSM  Randomization and trial supply management  
RBC  Red Blood Cell  
SOFA  Sequential Organ Failure Assessment  
SAE  Serious Adverse Event  
SD Standard Deviation  
SARS -COV -2 Severe Acute Respiratory Syndrome Coronavirus 2  
SRC  Safety Review Committee  
SaO2  Oxygen  Saturation   
SC Subcutaneous  
SAP Statistical Analysis Plan  
Tmax Time reach the peak concentration  
T1/2 Elimination half -life 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  24  
 TCR  Tissue -cross Reactivity  
TK Toxicokinetic  
TCO2  Total Carbon Dioxide  
TEAE  Treatment  Emergent Adverse Event  
TB Tuberculosis  
Vss V olume of Distribution at Steady State  
Vz V olume of distribution  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  25  
 1. Background  
Granulocyte -Macrophage Colony -Stimulating Factor (GM -CSF), also known as Colony -
Stimulating Factor 2 (CSF2), is a member of the colony -stimulating factor family of 
hematopoietic growth factors. It was first known as  an in vitro inducer for bone marrow 
progenitor cells to differentiate and proliferate into a single colony. GM -CSF is a monomeric 
glycoprotein cytokine, which may be produced by many cells including myeloid cells, dendritic 
cells, T cells, B cells, non -hematopoietic cells (such as endothelial ce lls, chondrocytes and 
alveolar epithelial cells) and even tumor cells  (Avci et al., 2016) . GM-CSF binds to heterodimeric 
receptors on bone marrow cells and neutrophils and activates GM -CSF receptors to initiate a 
variety of downstream signaling pathways, including Janus kinase signal transducer 
transcription - suppressor of cytokine signaling (J AKSTAT -SOCS), mitogen -activated protein 
kinase (MAPK), phosphatidylinositol 3 kinase (PI3K), and nuclear factor ĸB signaling pathway 
(NF-ĸB) (Hansen et al., 2008 ; Jenkins et al., 1998 ; Sato et al., 1993 ; Broughton et al., 2015;  
Hercus et al., 2017 ).     
GM-CSF, as a key upstream trigger factor in the inflammatory cytokine cascade, can enhance 
the effects of neutrophils and macrophages, to increase the expression of adhesion molecules, 
produce inflammatory cytokines and activate the phagocytosis. In addition, GM -CSF is also an 
important cytokine that induces the polarization of monocytes to the inflammatory M1  
phenotype and promotes the activation of macrophages, and the macrophages secrete a large 
number of inflammatory cytokines such as IL -6, TNF -α, etc., to involve in tissue inflammation  
(Hamilton , 1980 ). 
Indeed, the strong pr oinflammatory effects of GM -CSF make it a prime target in acute 
inflammatory conditions where elevated GM -CSF has been implicated in orchestrating a 
cytokine storm. At least three such syndromes share immunological and pathologic features of a 
cytokine sto rm: chimeric antigen receptor (CAR) -T cell therapy related cytokine release 
syndrome (CRS) and neurotoxicity, macrophage activation syndrome (MAS) and most recently, 
acute respiratory distress syndrome (ARDS) in severe coronavirus disease (COVID -19) cases 
caused by SARS -CoV-2 (severe acute respiratory syndrome coronavirus 2).  
CAR-T therapy is revolutionizing cancer treatment, but its application is limited by life -
threatening toxicities such as CRS and neurotoxicity ( Gust, 2019 ) attributable to hyperactive T 
cells and monocytes/macrophages. It has been reported that GM -CSF neutralizing antibody 
during CAR -T therapy prevented CRS and neuroinflammation and both GM -CSF neutralization 
and GM -CSF knockout in CAR -T cells enhanced antit umor activities in a mouse ALL xenograft 
model ( Figure 1 , Sterner  et al. , 2019 ). In addition, GM-CSF inactivation in this setting abolished 
macrophage -dependent secretion of factors, including monocyte chemoattractant protein 1 
(MCP -1), IL -6, and IL -8 (Sachdeva M, 2019 ). Compared to tocilizumab that has been widely 
used to treat cytokine storm caused by CAR -T cells, GM -CSF antibodies can achieve better 
treatment effect, especially in regu lating the broad spectrum of cytokines and inhibiting 
neurotoxicity.  Based on these findings, a clinical trial of GM -CSF antibody lenzilumab in CAR -
T therapy is planned  (Sterner  et al. , 2019 ). 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  26  
 Figure 1. GM -CSF antibodies inhibited the release of cytokines caused by CAR -T cells  (Sterner  et al. , 2019 ).  
 
Figure 2. Infection of SARS -CoV-2 Caused Hyperactivation of T helper cells  to Drive Aberrant 
Monocyte Activation  
 
Both T cells and monocytes produce large amounts of cytokines and chemokines which feed 
forward on the immune cells to precipitate a cytokine storm and tissue damage ensues. GM -CSF 
neutralization could stop this cycle. ( Figure 2  from Zhou Y , 2020 ; caption added).  
In the recent COVID -19 epidemic caused by the coronavirus SARS -CoV-2 in China, 10 -20% of 
the pneumonia patients developed severe or critical conditions that required intensive care. These 

Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  27  
 complications included ARDS, multiple organ failure and sometimes de ath. The clinical features 
(Huang, 2020 ) and immunopathology ( Xu, 2020 ) of patients with COVID -19 in China have now 
been reported, and they remarkably resembled those found in SARS ( Channappanavar, 2017 ). 
Common features among COVID -19 patients particularly those seriously or critically ill 
included lymphopenia and significantly higher than normal levels of inflammatory cytokines 
(IL-1, IL-7, IL -8, IL -9, IL -10, basic FGF, G -CSF, GM -CSF, IFN -γ, IP-10, MCP -1, MIP -1A, 
MIP-1B, PDGF, TNF -α, and VEGF ) (Huang, 2020 ). Most studies also reported massive 
production of IL -6, CRP, D -dimer and ferritin – all consistent with cytokine storm ( Wang, 2020 ). 
Importantly, lung pathology revealed heavy interstitial lymphocytic infiltrates  along with diffuse 
alveolar damage with fibromyxoid exudates, multinucleated giant cells  and hyaline membrane 
formation, indicative of ARDS ( Xu, 2020 ). Interestingly, these pathological features and lung 
CT imaging characteristics are also remarkab ly similar to those reported for a subset of systemic 
Juvenile Idiopathic Arthriti s (JIA) patients that developed MAS that l ed to severe 
immunopathology and lung disease ( Schulert, 2019 ). Finally , peripheral blood mononuclear cell 
(PBMC ) immunophenotyping showed an abundance of highly active GM -CSF-producing T 
helper ce lls and pathogenic monocytes in COVID -19 patients ( Xu, 2020 ; Zhou, 2020 ).  
It seems clear from these recent reports that severe COVID -19 bears all the hallmarks of a 
cytokine storm instigated by exuberant immune cells pro ducing GM -CSF and IL -6. They drive 
aberrant monocyte and T cell activation which in turn produce more cytokines and chemokines 
in a feed forward cycle that culminates in profound tissue injury, airway constriction, vascular 
collapse and organ failure. With out intervention, the clinical course is expected to be dire for 
COVID -19 patients in severe or critical conditions. Currently, based on the experience of IL -6R 
antibody tocilizumab in managing CAR -T induced CRS, tocilizumab is being tested for reducing 
cytokine storm and its complications in a clinical trial of COVID -19 patients. Based on the 
analysis above and progress made in CAR -T therapy with the introduction of GM-CSF inhibition , 
GM-CSF neutralizing antibodies such as TJ003234 may prevent or curb cyto kine storm and 
immunopathology in COVID -19 and consequently buy more time for viral clearance.  
TJ003234 is a recombinant anti -GM-CSF humanized monoclonal antibody independently 
developed by I -Mab Biopharma Co., Ltd. At present, a number of preclinical stud ies have been 
conducted on TJ003234, demonstrating that TJ003234 is a specific and effective antagonist of 
human GM -CSF/GM -CSFR pathway. TJ003234 has shown significant inhibitory effect on GM -
CSF mediating GM -CFSR signaling in vitro and in vivo. Blocking t he biological activity of GM -
CSF suppresses the activation of pro -inflammatory monocytes, leading to the potential  clinical 
benefits to patients with cytokine storms.  
In December 2018, the US F ood and Drug Administration ( FDA ) approved the first study of 
TJ003234 for human use in healthy volunteers. The phase I study was expected to obtain safe 
tolerated doses and pharmacokinetic characteristics of TJ003234 in humans, and currently the 
study has been completed. In this first hu man study, a single dose of TJ003234 up to 10 mg/kg 
in healthy subjects was well tolerated. The maximum tolerated dose was not reached. The 
increased TJ003234 exposure (C max and AUC) was roughly proportional to the increase in dose. 
The T 1/2 was about 3 we eks within the test dose range of 0.3mg/kg to 10mg/kg. The clearance 
rate of TJ003234 decreased with increasing dose. The volume of distribution decreased slightly 
with the increasing dose. In the subjects in 3 mg/kg and 10 mg/kg cohorts, TJ003234 inhibite d 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  28  
 GM-CSF-stimulated pSTAT5 levels by more than 90% for up to 2 weeks in 4 hours after dosing  
(full clinical study report submitted to FDA in January 2020 ).  
1.1. Preclinical Studies  
For information on TJ003234 preclinical studies, refer to the Investigator ’s Brochure . It is 
summarized as follows.    
1.1.1 Toxicological study  
The toxicology studies of TJ003234 include toxicity pre -test in cynomolgus monkeys, 
toxicology and toxicokinetic tests in cynomolgus monkeys after being given TJ003234 by 
repeated intravenous i njection for 4 weeks and recovery for 30 days, potential cross -reactions of 
TJ003234 to human and monkey tissues and in vitro hemolysis test ing of TJ003234 in rabbit 
blood erythrocytes.  
In the toxicity pre -test in cynomolgus monkeys, a control group and test groups (TJ003234 
Solution for Injection at doses of 20.65, 61.95, 216.2 mg/kg respectively) were established. 
Animals were treated  once a week for 3 consecutive weeks (3 times in tota l). No mortality 
occurred in the study, and all animals survived to the planned necropsy. No obvious TJ003234 -
related clinical symptoms, changes in body weights, food intake, and related hematological or 
coagulation parameters and clinical biochemical para meters were observed.  
In a pivotal Good Laboratory Practice ( GLP )-compliant toxicity study, 40 cynomolgus monkeys 
were randomly divided into 4 groups (5 animals/sex/group). On Days 1, 8, 15, 22, and 29 (4 -
week exposure), animals were administered by intra venous injection of the solvent control or 
test article (TJ003234 of 20, 60 or 200 mg/kg, 5 times in total). No Antidrug Antibody ( ADA ) 
formation was detected for all animals when the systemic exposure was reached, and no 
TJ003234 -related deaths or morbidity occurred.  
During a post -mortem recovery examination, a male animal had minimal congestion and 
multifocal alveolar protein in the lungs in the 20 mg/kg dose group. The alveolar protein was 
characterized by eosinophilic fibers and fluids in the alveoli, with a minimal increase in the 
number of alveolar macrophages with normal morphology. The animal ’s lung tissues showed 
negative by oil red O and PAS staining. Lung tissue SP -A and SP -D showed no interalveolar 
staining, and SP -B showed slight staining in a small number  of alveoli, which was considered 
non-specific and believed not to be related to PAP (pulmonary alveolar proteinosis). This animal 
was normal by clinical observation and had normal respiratory functions throughout this study. 
The lung changes i n male monkey were acute in nature and were considered to be caused by 
stress before or during euthanasia. Similar changes were not observed at higher dose levels or 
final necropsy. These data suggested that the animal ’s alveolar staining was not related t o PAP.   
During the terminal necropsy, a male animal in the 200 mg/kg group was found to have focal 
neuronal degeneration, edema, and a glial scar under microscopy. Given the low incidence of 
this change, these lesions were likely to be incidental and were  not related to the test substance. 
During the terminal necropsy, a male animal in the 200 mg/kg group was found to have 
pulmonary granulomas, and the gross observations showed multifocal yellowing of the lung's 
head lobe, middle lobe and caudate lobe and yellow lumps near the lung hilus. Since oil red O 
and PAS stains showed negative and SP -A, SP -B and SP -D in the alveoli were not specifically 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  29  
 stained, the animal's lung findings were not much related to the PAP. Although these lung 
changes occasionally occ urred in background lesions of non -human primates, the effect of the 
test substance on the immune system that may affect the original lesions could not be completely 
ruled out.  
Based on the above results, the No -Observed -Adverse -Effect Level (NOAEL) dose of TJ003234  
in cynomolgus monkeys was 60 mg/kg.  
1.1.1.1  Tissue -cross Reactivity in Human and Cynomolgus Monkey  
In this GLP -complaint tissue -cross reactivity ( TCR ) study, Biotin -TJ003234 (2.5, 5 and 10 
µg/mL), with cryo -sections from histologically normal frozen human and cynomolgus monkey 
tissues (panels of 40 tissues for human and cynomolgus monkey; 3 donors/panel) was assessed 
in this study. All tissues were vali dated by staining method. The positive control of the study was 
GM-CSF protein.  
Specific positive staining was observed with biotin -TJ003234 in secretory cells within tissues of 
the gastrointestinal tract in the human and cynomolgus money tissues panels ex amined. 
Additional specific positive staining was observed with biotin -TJ003234 in epithelial cells in 
cynomolgus monkey lung and parotid. The specific positive staining observed is consistent with 
GM-CSF expression, no tissue cross -reactivity was observed . 
1.1.1.2 In vitro Hemolysis Assay  
In this GLP -complaint hemolysis study, approximately 15 mL of blood was collected from a 
male New Zealand white rabbit via a jugular vein. Red blood cells (RBC) were suspended in 
0.9% sodium chloride injection solution to  a final concentration of 2%. The hemolytic potential 
of TJ003234 at concentration of 105.5 mg/mL was tested. After TJ003234 was added to the 
samples, the tubes were placed into a water bath set at 37 ℃ ± 0.5 ℃ for 3 hours and observed 
once every 15 minute s during the first hour and every hour during the last two hours for 
hemolytic potential.  
There was no hemolysis noted in RBC incubated with TJ003234 (105.5 mg/mL). There was also 
no RBC coagulation noted. TJ003234 at concentration of 105.5 mg/mL had no he molytic 
potential.  
1.1.1.3 Immunotoxicity and immunogenicity  
The immunotoxicity study was carried out t ogether with the 4 -week toxicology study in 
cynomolgus monkeys. The cytokines are one of important immune function parameters. No 
changes in cytokines were found after intravenous injection of TJ003234. The concentration and 
change of cytokine levels at al l time points during the dosing period on Day 1 and Day 22 in the 
TJ003234 group were similar to those in the control group, and the values were within the 
historical variation range, without any toxicological significance. In addition, TJ003234 
specifical ly bound and neutralized the secreted cytokine GM -CSF, which was not a cell target. 
Therefore, TJ003234 was expected to have a very low risk of inducing cytokine release 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  30  
 syndrome in human bodies, so human whole blood or PBMCs was not used for cytokine rele ase 
analysis. All samples were negative for anti -drug antibodies during the dosing and recovery 
periods;  therefore, no anti-drug antibody ( ADA ) formation was detected, which proved that 
TJ003234 had low preclinical immunogenicity.  
1.1.2 Pharmacological Studies  
Pharmacological studies included in vitro and in vivo pharmacological studies. Studies have 
shown that TJ003234 can block the GM -CSF/GM -CSFR interaction, prevent GM -CSFR -
induced signaling pathways, and thereby neutralize the biological activity of GM -CSF. By 
inhibiting the functions of macrophages, TJ003234 can reduce the autoimmune responses. 
TJ003234 did not show antibody -dependent cell -mediated cytotoxicity (ADCC) effect on human 
monocytes and complement dependent cytotoxicity (CDC) effect on human PBMC . The 
evaluation of the effects of TJ003234 on the in vitro monocyte activation to mimic the viral RNA 
stimulation demonstrated that TJ003234 treatmen t could suppress the activation of as well as 
cytokine production by proinflammatory monocytes.  
1.1.2.1 In vitro Pharmacology  
As shown in  Table 2 , TJ003234 was characterized through a series of in vitro studies to describe 
1) cross reactivity with GM -CSF from various species; 2) binding specificity to human GM -CSF 
over its structurally and functionally close related proteins; 3) ability to block th e interaction of 
GM-CSF with GM -CSF receptor (CD116 or GM -CSFR); 4) ability to inhibit GM -CSF mediated 
STAT5 phosphorylation in PBMCs and whole blood; 5) binding profiles to FcRn, Fc γ receptors 
and C1q ; 6) ADCC and CDC study ; 7) inhibition of in vitro mono cyte activation  which is used 
to mimic the COVID -19 viral RNA stimulation of primary monocytes . 
Table 2. Results of in vitro pharmacological studies  
Test Item  Test 
System  Test Results  
 Cross -reactivity of TJ003234 against different 
species of antigens  ELISA  The EC50s of TJ003234 against human and monkey GM -
CSF antigens were 13.22 ng/mL and 8.44 ng/mL, 
respectively, with similar binding effect. TJ003234 did 
not bind to mouse and rat GM -CSF antigens.  
Antibody specificity of TJ003234  ELISA  TJ003234 could bind human or monkey GM -CSF, with 
EC50 of 6.435 -6.722 ng/mL and 6.536 ng/mL, 
respectively. TJ003234 could not bind to human G -CSF, 
M-CSF, IL -3 or IL -5.    
Antibody receptor ligand blocking detection o f 
TJ003234  ELISA  Two independent tests showed that the half -maximum 
blocking concentrations (IC50) of TJ003234  block the 
binding of human GM -CSF to its receptor CD116 were 
112.4 ng/mL and 122.1 ng/mL, respectively, indicating 
that TJ003234 could  effectiv ely block the binding of 
human GM -CSF to CD116.  
Effect of TJ003234 on GM -CSF-mediated FACS  TJ003234 could effectively block STAT5 
phosphorylation in recombinant human -derived or 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  31  
 Test Item  Test 
System  Test Results  
STAT5 phosphorylation signals  cynomolgus monkey GM -CSF-mediated PBMCs. The 
IC50 of its inhibition of human -derived GM -CSF-
mediated STAT5 phosphorylation was 0.34 -1.70 ng/mL, 
and its IC90 was 4.15 -12.76 ng/mL. The IC50 of its 
inhibition of cynomolgus monkey GM -CSF-mediated 
STAT5 phosphorylation was 0.11 -4.54 ng/mL, an its IC90 
was 0.62-22.07 ng/mL.  
Roles of TJ003234 on STAT5 phosphorylation 
induced by GM -CSF activation in human whole 
blood  FACS  Antibodies could neutralize the activation of the GM -
CSF-induced STAT5 phosphorylation pathway in a dose -
dependent manner. IC50s of donors 1, 2 and 3 were 0.35 
μg/mL, 1.81 μg/mL, 0.44 μg/mL, respectively; and the 
IC90 of donors 1, 2 and 3 were 3.18 μg/mL, 4.67 μg/mL, 
1.55 μ g/mL, respectively.  
Affinity of TJ003234 
antibody to human 
GM-CSF antigen       
Biacore  The three batches of antibodies had strong affinity to the 
human antigen GM -CSF, and there was no significant 
difference between the three batches of antibodies.  
ADCC and CDC 
Effects of TJ003234        
ELISA  TJ003234 did not show antibody -dependent cell -
mediated cytotoxicity (ADCC) effect on human 
monocytes and complement dependent cytotoxicity 
(CDC) effect on human PBMC.  
Binding affinity of TJ003234 antibody to FcRn, 
Fcγ receptor and C1q  Biacore  The affinity between the antibody and each Fc receptor 
and complement C1qB was as follows (in descending 
order):  CD64, C1qB, CD16a (176Val), CD16a 
(176Phe), FcRn , CD32a, CD16b, CD32b.  IgG1 had a 
high affinity to CD64, but had a relatively low affinity to 
CD32. The above test results were consistent with the 
typical characteristics of IgG1, and there was no 
significant difference between the three batches of 
antib odies.   
Inhibition of in vitro monocyte activation by 
TJ003234  Luminex  TJ003234 treatment significantly decreased the 
production of proinflammatory cytokines and 
chemokines by activated monocytes including  IL-5, IL -7, 
IL-9, IL -10, IL -12p70, IL -13, IL -15, IL-17A, bFGF and 
Eotaxin .  
 
1.1.2.2   In vivo Pharmacology  
1.1.2.2.1  In vivo Efficacy of Repeat Dose TJ003234 on Type II Collagen Induced  Arthritis 
(CIA) Model in Cynomolgus Monkeys  
The in vivo therapeutic efficacy of TJ003234 for type II collagen induced arthritis was evaluated 
in cynomolgus monkeys with overt arthritic symptoms. Seventeen female cynomolgus monkeys 
were randomly assigned to 3 groups and received either no immunizatio n and no administration 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  32  
 (n=1), or immunization and vehicle (n=8) or test article (n=8, TJ003234 at 40 mg/kg).  
Animals that developed arthritis were randomly assigned to 2 groups (8F/group) and 
administered vehicle or 40 mg/kg TJ003234 by intravenous ( IV) injection once a week for 4 
doses. Arthritis severity was quantified by joint incidence (# of inflamed joints over the total # 
of joints analyzed) and arthritis score. Proximal interphalangeal (PIP) area was also applied to 
quantify joint swelling of arthri tis. Additionally, phosphorylation of STAT5 downstream of GM -
CSFR activation was used as a proximal pharmacod ynamic ( PD) marker reflecting the TJ003234 
mediated blockade of GM -CSF signaling, and was evaluated using PBMCs isolated from 
monkeys before or 24 hours after TJ003234 administration by FACS.  
Figure 3. In vivo Efficacy of Repeat Dose TJ003234 on Type II Collagen Induced Arthritis (CIA) 
Model in Cynomolgus Monkeys  
Joint Incidence
-1 0 1 2 3 4 5010203040
Vehicle
TJ-M2(40mg/kg)
weeks after treatmentJoint Incidence (%)
Score
-1 0 1 2 3 4 5020406080
Vehicle
TJ-M2(40mg/kg)
weeks after treatmentArthritis Score
 
a b 
PIP Incidence
-1 0 1 2 3 4 50204060
Vehicle
TJ-M2(40mg/kg)
weeks after treatmentIncidence (%)
PIP Area
-5-4-3-2-1 012345020406080
Vehicle
TJ-M2(40mg/kg)
weeks after treatmentArea(cm2)
 
c d 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  33  
 
chang of PIP
-1 0 1 2 3 4 5-15-10-5051015
Vehicle
TJ-M2(40mg/kg)
weeks after treatmentChange percentage  (%)
020406080
Pre Post Pre Post
Vehicle
(n=8)TJ-M2
(n=7)p = 0.19 p = 0.004% of pSTAT5 positive 
e f 
Comments : Joint incidence (a), arthritis score (b), PIP incidence (c), PIP Area (d), PIP area 
change percentage (e) and % of pSTAT5 positive cells in PBMCs (f) in CIA monkey model  
As shown in Figure 3 , the treatment at 40 mg/kg of TJ003234 could significantly reduce the 
severity of CI A, indicating that TJ003234 is effective in treating CIA in this model.  
1.1.2.2.2   Dose response relationship of TJ003234 in monkey CIA Model  
Using the same CIA monkey model, a dose -response study was conducted to establish the PK/PD 
relationship of TJ003234. Twenty -eight female cynomolgus monkeys were randomly assigned 
to 4 groups and received immunization and 0, 3, 10 and 30 mg/kg TJ003234 onc e via IV injection.  
Similar clinical endpoints (joint incidence, arthritis score, PIP incidence, PIP Area, PIP area 
change percentage) and proximal PD marker (phosphorylation of STAT5) were used in this study 
to evaluate the in vivo efficacy. As shown in  Figure 4.  Dose response relationship of TJ003234 
in monkey CIA Model , the joint incidence was not affected by treatment with TJ003234; the 
mean arthritis  scores were progressed in a decreased fashion after the TJ003234 treatment in all 
test groups compared to control group, yet no dose -response was found; no consistent difference 
in PIP incidence and PIP area between vehicle control and TJ003234 treatment;  the treatment at 
30 mg/kg of TJ003234 significantly reduced the PIP area in week 2 compared with week 1; 
treatment with TJ003234 (3, 10, or and 30 mg/kg once via IV injection) reduced pSTAT5 levels 
when compared to the vehicle control group.  
Figure 4. Dose response relationship of TJ003234 in monkey CIA Model  
 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  34  
  
a  
b 
 
c 
PIP area
week -3* week 0* week 1* week 2*2025303540
Vehicle n=5
TJ-M2 3mpk n=6
TJ-M2 10mpk n=6
TJ-M2 30mpk n=6
weeks after treatmentPIP area(cm2) 
d 
 
0 310 30050100150
Week 1*
Week 2**
Tj-M2 dose (mpk)PIP Area change (%)PIP Area change(%) 
e 
pSTAT5 in cyno CIA model
Pre Post Pre Post Pre Post Pre Post0204060
vehicle TJ-M2
(3 mg/kg)TJ-M2
(10 mg/kg)TJ-M2
(30 mg/kg)% of pSTAT5 positive 
f 
Comments: Joint incidence (a), arthritis score (b), PIP incidence (c), PIP Area (d), PIP area 
change percentage (e) and % of pSTAT5 positive cells in PBMCs (f) following 0, 3, 10, 30 
TJ003234 single IV injection in CIA monkey model   
A systematic exposure study was conducted for all animals. After a single intravenous injection 
of TJ003234 into CIA model monkeys, the mean peak concentrations (C max) at 3, 10, and 30 
mg/kg were 76.137, 236.313, and 572.236 μg/mL, respectively; the  mean areas under 
concentrati on-time curve were 2143.691, 9361.553, and 14134.021 μg • hr/mL, respectively. 
Based on the mean C max and AUC last, TJ003234 exposure rose with proportionally increased dose 
levels from 3 mg/kg to 30 mg/kg.      

Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  35  
 In summary, a single dose of TJ003234 within the range of 3 to 30 mg/kg can inhibit the 
development of arthritis symptoms without exhibiting a significant dose -dependence:  the 
systemic exposures (Cmax and AUC) within the dose range increase proportionally with the dose.   
1.1.3 Pharmacokinetic study  
1.1.3.1  Single -dose Pharmacokinetics  
Based on the cross -reaction of TJ003234 with cynomolgus GM -CSF antigen and no affinity with 
rodent GM -CSF antigen and the fact that TJ003234 can block the GM -CSF-mediated STATS5 
phosphorylation signals in the cynomolg us monkey -derived PBMCs, cynomolgus monkeys 
were selected as the sole animal species. In a single -dose pharmacokinetic study, cynomolgus 
monkeys (3 animals/sex/group) were given 5, 25, and 50 mg/kg of TJ003234 by intravenous 
injection respectively. No sex -specific difference in systemic exposure were observed, and C max 
and AUC 0-last increased proportionally in the last dose with the range of 5 -50 mg/kg. The 
Cmax/dose and AUC 0-last/dose in all dose groups were similar within the dose range of 5.0 mg/kg 
to 50  mg/kg, indicating that TJ003234 met the linear pharmacokinetic behaviors within the dose 
range. With the entire dose levels, the mean elimination half -life (T 1/2) ranged from 9.0 to 10.0 
days, the clearance (CL) ranged from 0.332 to 0.406 mL/h/kg, the app arent volume of 
distribution (V z) ranged from 114 to 126 mL/kg, C max was 112-1220μ g/mL and AUC 0-last was 
14800 -124000 μ g · h/mL.  
The bioavailability of TJ003234 following subcutaneous injection was studied in cynomolgus 
monkeys following a single intraven ous injection at 5 mg/kg and a single subcutaneous injection 
at 5 mg/kg, 25 mg/kg and 50 mg/kg, respectively. A linear subcutaneous pharmacokinetic profile 
was observed across three subcutaneous ( SC) dose levels, with bioavailability of 77.4%, 78.8%, 
72.6% , respectively. The rate of elimination was similar following IV and SC routes, indicating 
elimination of TJ003234 was independent of the route of administration in cynomolgus monkeys. 
No ADA was detected throughout the study.  
1.1.3.2  Repeat -dose  Pharmacokinetics  
The toxicokinetic (TK) profile of TJ003234 across repeated IV doses were determined in 
conjunction with a GLP -compliant repeat -dose toxicology study in cynomolgus monkeys. In this 
study, 40 cynomolgus monkeys were randomly assigned into 4  groups (5/sex/group) and 
administered TJ003234 at 0, 20, 60 or 200 mg/kg via IV injection once weekly (Q1W) for a total 
of 5 doses.  
No significant gender differences in systemic exposure (C max and AUC 0-t) following the 1st and 
4th doses were observed. The  systemic exposure increased dose proportionally after the 1st dose 
from 20 to 200 mg/kg. There were no significant differences in the concentration -time curves 
among individual animals within each dose level. Following the 4th dose, toxicokinetic 
paramete rs, including time of maximum concentration (T max), C max, AUC 0-t, and clearance (CL) 
were similar to those following the first dose. Exposure did not decrease significantly following 
the 4th dose when compared to the 1st dose, indicating the absence of an increased clearance due 
to potential neutralizing ADA formation. The immunogenicity results confirmed that all samples 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  36  
 were detected as anti -TJ003234 antibody negative in the dosing phase. Mild accumulation was 
noticed in AUC 0-t and C max at all dose levels : for the 4th vs 1st dose, the ratio of C max was 1.27, 
1.29, 1.15, and the ratio of AUC 0-t was 1.49, 1.41, 1.35, for 20, 60, 200 mg/kg dose levels, 
respectively.  
1.2. Clinical Study  
The US FDA approved the Investigational New Drug ( IND) of TJ003234 in healthy volunteers 
in December 2018. The phase I trial was designed as a single -center, randomized, double -blind, 
placebo -controlled, single -dose escalation study . 
The study objectives were to evaluate safety, tolerability, PK, PD, and immu nogenicity of 
TJ003234  following a single dose . This study enrolled 32 healthy subjects at the dose levels of 
0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg. Eight subjects were randomized at a ratio of 3:1 in 
each dose cohort to receive either TJ003234 or place bo. In the first cohort, to mitigate any 
unforeseen safety issues, the first 4 of the 8 subjects were individually dosed at intervals that 
were, by protocol, at least 24 hours apart. In each study cohort, subjects were screened within 27 
days prior to admi ssion to the site. Subjects were admitted to the site on the day prior to dosing 
(Day -1) for pre -dose study procedures and randomization. On dosing day (Day 1), a single dose 
of TJ003234 was administered IV over a maximum 2 -hour period. Subject s were obse rved 
overnight. On Day 2, after completion of the study procedures and assessments, subjects were 
discharged from the site. The 7 -day dose -limiting toxicity (DLT) observational period started at 
the completion of dosing (end of infusion [EOI]). The study p eriod was defined as the time of 
dosing through the end of the study (a duration of 90 days). Subjects returned to the site for 
outpatient visits on Days 3, 5, 8 (week 1), 15 (week 2), 29 (week 4), 43 (week 6), 57 (week 8), 
71 (week 10) and 90 (week 13). D ay 90 was considered the end of study (EOS) visit.  
Dose escalation occurred sequentially after review of safety data for each dosing cohort by the 
safety review committee (SRC). Dose escalation to the next dose level proceeded uninterrupted 
as long as no p re-defined DLT or stopping criteria were met. According to the protocol, if the 
maximum tolerated dose ( MTD ) was not reached during dose escalation, the maximum 
administered dose (MAD) was defined as 10 mg/kg.  
As of January 2020, the study has been completed and a clinical study report has been issued. 
Thirty -two (32) subjects enrolled into and completed TJ003234RAR101. There were no 
interruptions in dosing or early withdrawals. The Safety, PK, and PD Population s each include 
all 32 subjects. All treatment groups included both males and females as well as both black 
(43.8%) and white subjects (43.8%). There were no observable differences between the treatment 
groups that were anticipated to affect assessment of o utcome. All major protocol deviations were 
reviewed by the medical monitor and determined to have no medical impact on the study.  
Safety Results:  
TJ003234 is well tolerated following a single IV dose up to 10 mg/kg in healthy subjects with 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  37  
 no maximum toler ated dose reached. The majority of adverse events ( AEs) were mild to 
moderate. No serious adverse events were reported during the study. Overall, 8 of the 24 subjects 
who received TJ003234 and 3 of the 8 subjects who were on placebo reported treatment -related 
treatment -emergent adverse events (TEAEs). The most common AEs experienced by subjects 
dosed with TJ003234 were headache (25%, grade 1/2) and protein urine (25%, grade 1). These 
AEs were also the most common AEs reported by subjects received placebo (3 7.5%, grade 1/2 
and 37.5%, grade 1, respectively). Two pulmonary AEs (Grade 1 cough and shortness of breath) 
were reported in one subject at Cohort 3 and were considered to be drug related. Two subjects 
from Cohort 1 and one subject from the Cohort 2 repor ted more than 20% decrease in FEV1 or 
FVC but the values were still within normal ranges, the changes were not observed in higher 
dose level cohorts. No clinically meaningful changes were observed in the dyspnea score.  
Pharmacokinetic Results:  
A summary o f TJ003234 PK parameters following a single ascending dose of 0.3 to 10 -mg/kg 
of TJ003234 administered to healthy subjects is presented below.  
Table 3. TJ003234RAR101: TJ003234 Serum Pharmacokinetic Parameters following Single 
Ascend ing Intravenous Dose of TJ003234 in Healthy Subjects (PK Population)  
Dose level  Cmax 
(µg/mL)  Tmax 
(h) AUC last 
(day*µg/mL)  AUC 0-∞ 
(day*µg/mL)  t1/2 
(day)  CL 
(mL/day)  Vss 
(L)  Vz 
(L)  
0.3 
mg/kg(n=6)  5.24 
(56.2)  1.26 
(1.00 , 1.38)  80.3  
(63.0)  85.7 
(66.0)  22.5 
(5.91)  290 
(68.2)  8.26 
(54.8)  9.15 
(62.5)  
1 mg/kg(n=6)  24.7 
(19.4)  1.29 
(1.27 , 1.30)  289 
(25.2)  298* 
(30.1)  20.5* 
(4.96)  258* 
(39.4)  5.71 
(34.0)  7.41* 
(17.9)  
3 mg/kg(n=6)  71.7 
(10.3)  1.70 
(1.70,  48.6)  1100  
(27.1)  1250* 
(22.3)  20.1* 
(3.20)  200* 
(12.9)  5.26 
(4.76)  5.75* 
(5.60)  
10 mg/kg(n=6)  258 
(13.6)  3.58 
(1.77 , 25.2)  3680  
(27.2)  3860  
(29.9)  20.6 
(3.49)  178 
(37.1)  4.63 
(20.7)  5.23 
(20.9)  
Cmax, AUC last, AUC 0-∞,, CL, V ss, and Vz are presented as geometric mean (%CV). t 1/2 is presented as mean (SD). T max is 
presented as median (min, max).  
*At the 1 mg/kg and 3 mg/kg dose levels, the sample size reported for AUC 0-∞, t1/2, CL, and Vz  is 5 subjects not 6 because 
each had too much variability in their concentration -time data and thus too low an r2 to be acceptable for using the data in 
calculating these parameters.  
Pharmacodynamic Results:  
Four hours after dosing, the induction of pSTAT5 by ex vivo  GM-CSF stimulation in the 
monocyte population was inhibited by at least 70% compared to the placebo following a single 
dose of TJ003234 for all dose groups. The induction of pSTAT5 by GM -CSF stimu lation was 
inhibited by 94.1% at 4h postdose and 92.6% at 336h postdose following a single dose of 3mg/kg 
TJ003234. A comparable inhibitory effect was observed at 10mg/kg cohort, i.e. 95.3% inhibition 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  38  
 at 4hour postdose and 91.7% at 336 hour postdose. The i nhibition was sustained for 2 weeks at 
3 mg/kg and 10 mg/kg cohorts, suggesting the saturation of the pSTAT5 inhibition by the 
treatment at a 3 mg/kg dose and above.   
Immunogenicity Results:  
Two subjects in the 3 mg/kg TJ003234 cohort and one placebo subj ect were positive for ADA. 
The placebo subjec t was positive on Day 57 but negative on Day 90. One subject in the 3 mg/kg 
TJ003234 cohort  developed a positive response at the Day 57 timepoint and maintained it when 
tested on Day 90. The other subject in the  3 mg/kg TJ003234 cohort  was positive only on Day 
90. No subject in the 10 mg/kg dose level was positive for ADA.  
1.3. Benefits and Risks Assessment  
1.3.1 Benefit s 
Based on the anti -inflammatory action mechanism of GM -CSF antibody, preclinical study results 
of TJ003234 and inhibition of in vitro monocyte activation by TJ003234, we believe that 
TJ003234 has potential benefits for the treatment of severe COVID -19.  
1.3.2 Risk s 
Based on the results of preclinical studies conducted by I -Mab Biopharma and with reference to 
the published data in clinical studies of antibody with same/similar mechanism, the important 
potential risks of TJ003234 include:     
 Pulmonary alveola r proteinosis  
 Infections  
 Infusion -related reactions  
Pulmonary alveolar proteinosis (PAP)  
GM-CSF promotes alveolar macrophage proliferation, which plays a critical role in lung 
defenses and surfactant homeostasis through catabolism of surfactant lipids a nd proteins. 
Autoantibodies against GM -CSF have been associated with the development of idiopathic 
autoimmune PAP, in which abnormal accumulation of pulmonary surfactant protein occurs 
within the alveoli due to insufficient clearance by GM -CSF-starved macr ophages. Due to this 
association, there is a theoretical risk of developing PAP when long -term using therapeutic 
antibodies that target GM -CSF. No PAP has been indicated in TJ003234 non -clinical studies 
and the completed TJ003234 first -in-human (FIH) study  (TJ003234RAR101). No clinically 
significant findings were identified in terms of pulmonary function tests and respiratory related 
signs/symptoms in this FIH study.   
Infections  
 
Due to the biological mechanism of TJ003234, blocking the GM -CSF may inhibit t he functions 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  39  
 of macrophage and neutrophils, thus potentially may lead to risk of infections, especially long -
term using. No infections were reported from TJ003234 animal studies. In the completed 
TJ003234 study in healthy adults, 24 adults received TJ00323 4, there was one adult experienced 
nasopharyngitis, and one adult experienced vulvovaginal mycotic infection. One of 8 adults who 
received placebo developed otitis media.   
Infusion related reactions (IRR)  
All therapeutic monoclonal antibodies used for oncology and immunologic therapies have the 
potential to cause infusion related  reactions  (IRRs) . Symptoms vary with a wide spectrum of 
severity, ranging from mild fever and chills to life -threatening anaphyla xis with bronchospasm, 
and hypotension. Typically, IRRs  to monoclonal antibodies develop within 30 -120 minutes after 
the initiation of drug infusion, although symptoms may not show up until 24 hours. Most 
common symptoms of IRRs  are fever, chills, nausea, vomiting, diarrhea, itching, flushing, rash, 
changes in blood pressure and heart rate, dyspnea, chest discomfort, back and abdominal pain. 
The risk of IRR declines with each subsequent course of therapy. Although premedication can 
help to prevent and/or re duce the severity of infusion reactions, anaphylaxis generally cannot be 
prevented by premedication. No IRR was identified in TJ003234 previous completed FIH study.  
2. Objectives and Endpoints  
2.1. Objectives  
2.1.1.  Primary Objective  
To evaluate the efficacy and safety of TJ003234 in subjects with  severe novel Coronavirus 
pneumonia (COVID -19) with supportive care .  
2.1.2.  Secondary Objectives  
 To evaluate the effects of TJ003234 on cytokines in subjects with  severe COVID -19.  
 To assess the pharmacokinetics (PK) and im munogenicity potential of TJ003234 when 
administered as a single dose IV infusion in subjects with severe COVID -19. 
2.2. Endpoints  
2.2.1.  Primary Efficacy Endpoint  
Proportion (%) of subjects who are alive and free of mechanical ventilation a t Day 30  among 
subjects who are non -mecha nical ventilated at baseline . 
2.2.2.  Secondary Efficacy Endpoints  
Key Secondary Efficacy Endpoints:  
 Proportion (%) of subjects recovered by Day 14. Recovery is defined as the subject scoring 
a 3, 2, or 1 on the 8 -category ordinal scale as defined below by Day 14 and subsequently 
does not progress to a score ≥ 4 for the remainder of the study . If a subject scores 3 at 
baseline,  this subject is considered to be recovered if this subject ’s score improves to 1 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  40  
 or 2 by Day 14. 
8, death; 7, ventilation in addition to extracorporeal membrane oxygen (ECMO), continuous 
renal replacement therapy (CRRT) or pressors; 6, intubation an d mechanical ventilation; 5, 
non-invasive mechanical ventilation (NIV) or high -flow oxygen; 4, hospitalization with oxygen 
by mask or nasal prongs; 3, hospitalization without oxygen supplementation; 2, limitation of 
activities, discharge from hospital; and  1, no limitation of activities, discharge from hospital.  
• Proportion (%) of subjects recovered by Day 30. Sustained recovery is defined as the 
subject scoring a 3, 2, or 1 on the 8 -category ordinal scale as defined in the  key secondary  
endpoint by Day 30 a nd subsequently does not progress to a score ≥ 4 for the remainder 
of the study . If a subject scores 3 at baseline, this subject is considered to be recovered if 
this subject ’s score improves to 1 or 2 by Day 30.  
 All-cause mortality rate on Day 30.   
Other Secondary Efficacy Endpoints:  
 Time to  sustained  recovery among subjects alive by Day 30 [Time Frame: Day 1 through 
Day 30]: Day of sustained recovery is defined as the first day on which the recovered 
subject scores 3, 2 or 1 and maintains such score through Day 30 from the 8 -category 
ordinal scale as defined in the  key secondary  endpoint. If a subject is scored at 3 at 
baseline, day of recovery is defined as the day on which this subject ’s score improves to 
1 or 2  and maintain s such score through Day 30 . 
 Length of hospitalization . 
2.2.3.  Exploratory  Efficacy Endpoints  
• Improvement in clinical status (Day 7, Day 14 and Day 30)  
• Sequential Organ Failure Assessment score (SOFA score) (Day 7 and Day 14 from the 
day of dosing)  
• Change from baseline in PaO2/ FiO2 (Day 7 and Day 14 from the day of dosing)  
• Length of time to normalization of oxygen saturation which is defined as SpO2 ≥94% 
sustained minimum 24 hours  
• Percentage  of subjects requiring mechanical ventilation  at Day 7 and Day 14 from t he 
day of dosing . 
• Change from baseline in serum cytokines, e.g. IL -1RA , IL-1β, IL-2, IL -6, IL-7, IL-10, 
GCSF, GM -CSF, CCL2, CCL3, CCL17, CXCL10, TNF -α and IFN -γ, etc. (Day 2, Day 
3, Day 5, Day 7, and Day 14 from the day of dosing)  
• Change from baseline in D -dimer, cardiac troponin, LDH, and ferritin levels (Day 7 and 
Day 14 from the day of dosing)  
• Peripheral blood neutrophils -to-lymphocyte ratio (NLR)  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  41  
 2.2.4.  Safety Endpoints  
 Treatment -emergent Adverse events evaluated using the National Cancer Institute (NCI) 
Common Terminology Criteria for Adverse Events Criteria ( CTCAE) (version 5.0),  
 Changes from baseline in clinical laboratory parameters, physical examinations, vital 
sign measurements, 12 -lead electrocardiograms (ECGs), and radiographic lung imaging.  
3. Investigational Plan  
3.1. Study Design  
This trial is designed as a two-part study to evaluate the efficacy and safety of TJ003234 
administered by an IV infusion in subjects with severe COVID -19 with supportive care, and to 
assess the effect of cytokine  elevations on the disease as well as the effect of TJ003234 on the 
levels of cytokines.  
Figure 5: Study Design Schema  
 
 
3.1.1.  Part 1  
Part 1 is designed as a randomized, double -blind, placebo -controlled , 3-arm, parallel -group  study 
to evaluate the safety of TJ003234 in subjects with severe COVID -19. Potential subjects will be 
screened to assess their eligibility to enter the study within 3 days prior to study drug 
administration. A total  of 24  eligible subjects will be randomized at a r atio of 1:1:1 to receive 
either a single dose of 3 mg/kg TJ003234 , a single dose of 6 mg/kg TJ00324 or placebo, 
administered by IV infusion. Before and after the treatment, all subjects will be allowed to 
receive supportive care and/or additional treatment s for COVID -19 and its complications per the 
Investigator. Up to twenty -four subjects will be enrolled in Part 1.  If no more than 2 out of 8 
subject s experience a Grade ≥3 treatment -related AE within 7 days of the subjects receiving the 
study drug  in eithe r TJ003234 arm and no more than 4 out of 16 subjects experience a Grade ≥3 

Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  42  
 treatment -related AE within 7 days of the subjects receiving the study drug in both TJ003234 
arms combined , Part 2 will be initiated.  The end of Part 1 is defined as 30 days after the last 
subject is dosed , or until study termination.  
Enrolled subjects will complete follow -up visits for 30 days after dosin g to assess the safety and 
efficacy of the study drug. Subjects will be  followed un til the complete all study visits,  the subject 
(or their legally authorized representative ( LAR )) withdraws consent, the subject is lost to 
follow -up or the subject dies.  
3.1.2.  Part 2  
Part 2 is designed as a randomized, double -blind, placebo -controlled, 2-arm, parallel -group study 
to evaluate  the efficacy and safety of TJ003234 in subjects with severe COVID -19. Part 2 
contains two phases, the first phase, Phase 2, will enroll 120 subjects and the second phase, Phase 
3, will enroll approximately 450 subjects. The  data collected from Phase 2 will be used to make 
decision for Phase 3 and may be used to re -estimate sample size of Phase 3 portion. Potential 
subjects will be screened to assess their eligibility to enter the study within 3 days prior to the 
first dose a dministration. A total of 570 eligible subjects will be randomized at a ratio of 2:1 to 
receive either a single dose of TJ003234  or placebo, administered by intravenous infusion. 
Randomization will be stratified by age at randomization  (<60 years  versus ≥ 60 years ) and use 
of remdesivir (yes versus no) . Before and after the treatment, all subjects will be allowed to 
receive supportive care and/or additional treatments for COVID -19 and its complications per the 
Investigator.  
Enrolled subjects will complete  follow -up visits for 30 days after dosing to assess the safety and 
efficacy of the study drug. Subjects will be followed until the y complete all study visits, the 
subject meets the withdrawal criteria in Section 4.4  or the subject dies.  
3.1.2.1.  Pharmacokine tic (PK)  and Anti -Drug Antibody (ADA)  Subgroup  
In Part 2  Phase 2 stage , 40 subjects will be randomly assigned to a subgroup to collect  PK and 
ADA samples . PK samples will be collected  on Day 1  (predose and at End of Infusion) , Day 7 
and Day 14.  ADA samples  will be collected on Day 1 predose and Day 14 . Of these 40 subjects, 
30 will be from the 6 mg/kg TJ003234 treatment arm and 10 will be from the placebo arm.  
In Part 2 Phase 3 stage, 40 subjects will be randomly assigned to a subgroup to collect PK and 
ADA  samples. PK samples will be collected on Day 1 (predose and at End of Infusion), Day 7 
and Day 14. ADA samples will be collected on Day 1 predose and Day 14. Of these 40 subjects, 
30 will be from the 10 mg/kg TJ003234 treatment arm and 10 will be from the  placebo arm.  
3.1.3.  Study Populations and Sample Size  
Part 1 of the study will enroll up to 24 subjects  at a 1:1:1 ratio (3 mg/kg TJ003234 to  6 mg/kg 
TJ003234 to  placebo ). Part 2 of the study will enroll up to 570 subjects at a 2:1 ratio (TJ003234 
to placebo) .  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  43  
 3.2. Scientific Rationale for Study Design   
GM-CSF, as a key upstream trigger factor in the inflammatory cytokine cascade, can enhance 
the effects of neutrophils and macrophages, produce inflammatory cytokines  and activate the 
phagocytosis. In addition, GM -CSF is also an important cytokine that induces the polarization 
of monocytes to the inflammatory M1 phenotype and promotes the activation of macrophages, 
and the macrophages secrete a large number of inflamma tory cytokines such as IL -6 and TNF -
α, to involve in tissue inflammation  (Hamilton, 1980 ). The strong proinflammatory effects of 
GM-CSF make it a promising target in acute inflammatory conditions where elevated GM -CSF 
has be en implicated in orchestrating a cytokine storm. At least three such syndromes share 
immunological and pathologic features of a cytokine storm: chimeric antigen receptor (CAR) -T 
cell therapy related cytokine release syndrome (CRS), macrophage activation sy ndrome (MAS) 
and most recently, acute respiratory distress syndrome (ARDS) in severe coronavirus disease 
(COVID -19) cases caused by SARS -CoV-2 (severe acute respiratory syndrome coronavirus 2).  
In the recent COVID -19 epidemic caused by the coronavirus SAR S-CoV-2 in China, 
approximately 15 -30% of severe COVID -19 patients developed ARDS ( Wang, 2020 ; Huang, 
2020 ; Chen, 2020 ; Guan, 2020 ). Without in tervention, the clinical course is expected to be dire 
for severe COVID -19 patients. Therefore, there is a huge unmet medical need of therapy for 
severe COVID -19 patients. At present, there is no specific immune modulating therapy for 
severe COVID -19 patie nt. 
The clinical features ( Huang, 2020 ) and immunopathology ( Xu, 2020 ) of patients with COVID -
19 in China have now been reported, and they remarkably resembled those found in SARS 
(Channappanavar, 2017 ). Common features among COVID -19 patients, particularly those 
seriously or critically ill, included lymphopenia and significantly elevated levels of inflammatory 
cytokines including IL -1, IL -7, IL -8, IL -9, IL -10, basi c FGF, G -CSF, GM -CSF, IFN -γ, IP-10, 
MCP -1, MIP -1A, MIP -1B, PDGF, TNF -α, and VEGF. ( Huang, 2020 ). Massive production of 
IL-6, CRP, D -dimer and ferritin were also observed, which are all indicative of cytokine storm 
(Wang, 2020 ). Importantly, lung pathology revealed heavy interstitial lymphocytic infiltrates 
along with diffuse alveolar damage with fibromyxoid exudates, multinucleated giant cells and 
hyaline membrane formation, indicative of AR DS (Xu Z, 2020 ). Interestingly, these pathological 
features and lung CT imaging characteristics are also remarkably similar to those reported for a 
subset of JIA patients that developed MAS that led to severe immunopathology and l ung disease 
(Schulert, 2019 ).  
It seems evident from the recent reports that severe COVID -19 bears all the hallmarks of a 
cytokine storm instigated by exuberant immune cells producing GM -CSF and IL -6. They drive 
aberrant mon ocyte and T cell activation which in turn produce more cytokines and chemokines 
in a feed forward cycle that culminates in profound tissue injury, airway constriction, vascular 
collapse and organ failure ( Zhou, 2020 ). Peripheral  blood mononuclear cell (PBMC) 
immunophenotyping showed an abundance of highly active GM -CSF-producing T helper cells 
and pathogenic monocytes in COVID -19 patients (Xu, 2020 ; Zhou, 2020 ). A recent study  
published in Blood showed that GM -CSF antibodies have been demonstrated to effectively 
inhibit the cytokine storm caused by CAR -T cell therapy and reduce the levels of a series of 
inflammatory factors such as IFN -g, IL -6, MCP -1, MIP -1 in preclinical exper iments. In addition, 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  44  
 it can control the infiltration of immune cells such as T cells and macrophages into the central 
nervous system, and effectively inhibit the generation of neurotoxicity. Compared to tocilizumab 
that has been widely used to treat cytoki ne storm caused by CAR -T cells, GM -CSF antibodies 
may have better efficacy, especially in regulating the broad spectrum of cytokines and inhibiting 
neurotoxicity. Therefore, two clinical trials will be conducted to evaluate the therapeutic effects 
of GM -CSF antibodies or GM -CSF receptor antibodies on CAR -T cell -induced side effects such 
as cytokine storm and neurotoxicity  (Gilead, 2020 ). Currently, based on the experience of IL -6R 
antibody tocilizumab in managing CAR -T induced CRS, tocilizumab is being tested for reducing 
cytokine storm and its complications in a clinical trial of COVID -19 patients in China  (Chinese 
Clinical Trial Registry, n.d. ). GM-CSF neutralizing antibody such as TJ003234 may also has the 
potential to prevent or curb cytokine storm and immunopathology and thus earn more time for 
viral clearance, which may improve the overall clinical outcome of COVID -19 severe patients.  
 
3.3. Justification for Dose  
In this study, th e dose of TJ003234 has been predicted based on the results of safety, 
pharmacokinetics and pharmacodynamics from a single ascending dose study in healthy subjects, 
preclinical data, the safety data of similar GM -CSF antibodies in patients with rheumatoid 
arthritis, as well as the data of IL -6 antibody tocilizumab for treatment of cytokine storms. For 
TJ003234, a single dose escalation study in 32 healthy subjects has been completed. No dose 
limiting toxicity (DLT) was observed in the 0.3 mg/kg, 1 mg/kg, 3 m g/kg and 10 mg/kg dose 
groups. The maximum tolerated dose (MTD) was not reached. The half -life of TJ003234 was 
approximately 3 weeks and plasma concentrations increased proportionally with the dose over 
the range 0.3 mg/kg to 10 mg/kg. Pharmacodynamics sho wed similar levels of inhibition of ex -
vivo GM -CSF-activated pSTAT5 at doses of TJ003234 3 mg/kg and 10 mg/kg. Inhibition of 
more than 90% was reached at 4 hours after dosing and was maintained for 2 weeks  (full clinical 
study report submitted to FDA in Ja nuary 2020 ). 
The dosing regimen of TJ003234 in the Part 2 Phase 3 trial is amended as 10 mg/kg TJ003234 
or placebo based on the observed efficacy, safety, and PK data in the completed Part 2 Phase 2 
study. In Part 2 Phase 2 study  with patients with Covid -19, improved efficacy over the placebo 
arm was observed with an acceptable toxicity profile of TJ003234. At the same time, increased 
clearance of TJ003234 (0.02 L/hr in patients with Covid -19 compared to 0.009 L/hr in healthy 
subjects) was observed at a single dose of 6 mg/kg TJ003234, with a shorter half -life (6 days) 
than in healthy subjects (3 weeks). Therefore, a single dose of 10 mg/kg is expected to further 
improve the magnitude of efficacy improvement by providing higher exp osure than that of 6 
mg/kg dose in Covid -19 patients. Based on the observed PK data, the exposure of a single dose 
of 10 mg/kg TJ003234 in patients with Covid -19 is expected to be lower than that in healthy 
subjects. Therefore, an acceptable safety profile  is expected to be maintained, as the 10 mg/kg 
has been tested in healthy subjects with excellent safety profile. The dosing regimen of TJ003234 
in the Part 2 Phase 3 trial is amended as 10 mg/kg TJ003234 or placebo based on the observed 
efficacy, safety, and PK data in the completed Part 2 Phase 2 study.  
According to the preclinical toxicology study (Q 1W for 4 weeks), the No -Observed -Adverse -
Effect Level (NOAEL) dose in Cynomolgus monkeys was 60 mg/kg. Since molecular weight of 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  45  
 TJ003234 is >100 ,000 Da (146KDa) and administered intravenously, according to FDA 
guidance  stating that proteins administered intravascularly with molecular weight >100 KDa 
should be normalized to mg/kg as an exception to mg/m2 scaling approach  (CDER, 2005 ), the 
calculated Human equivalent dose (HED) based on NOAEL is also 60 mg/kg.  
GM-CSF antibodies have been reported to be well tolerated in clinical trials. Namilumab and 
KB003 are drugs with the same mechanism of action as the study drug and bo th were well 
tolerated at doses of 5 -6 mg/kg  (Huizinga, et al., 2017 ). The Phase IIb clinical trial of 
mavrilimumab, which is an antibody of GM -CSF receptor and has a similar mechanism of action 
as the study drug, showed no adverse reactions in the lung  (Burmester et al., 2017 ). The 
autoantibodies of GM -CSF are associated with the development of idiopathic autoimmune 
pulmonary alveolar proteinosis (PAP). There is a theoretical risk of developi ng PAP when 
therapeutic antibodies targeting GM -CSF are used. Non -clinical studies of mavrilimumab, a 
compound targeting GM -CSF receptor, showed that macrophage change in lung tissues was only 
observed in studies with dosing lasting more than 11 weeks (Ryan et al., 2014 ). Therefore, it is 
believed that the PAP is a long -term chronic development process and, the risk of PAP developed 
from drug exposure after a single dose is most likely to be low. In addition, we closely monitored  
pulmonary function up to 90 days and no clinical meaningful changes of pulmonary function 
was observed in the single dose escalation study  (full clinical study report submitted to FDA in 
January 2020 ), Taken together with the safety data in human and prec linical studies, we believe 
that a single dose of 3 mg/kg and 6 mg/k g TJ003234 will be safe in the patient population.  
Preclinical pharmacodynamics showed a treatment effect of <50% (as measured by an inhibitory 
effect on the GM -CSF/GM -CSFR signaling pathway) at a single intravenous infusion dose of 3 
mg/kg in the CIA (type II collagen -induced arthritis) model in cynomolgu s monkeys. The results 
from the in vitro monocyte activation assay to mimic the COVID -19 viral stimulation of primary 
monocytes confirmed that treatment of 10 μg/ml TJ003234 suppressed the pro -inflammatory 
cytokine production and activation marker expressi on, indicating that the dose of 3 mg/kg may 
be efficacious since the trough concentration of a single dose of 3 mg/kg exceeds 10 µg/ml in 
the Phase I clinical trial. On theoretical grounds, the GM -CSF levels will further increase in 
COVID -19 patients with cytokine storms compared to healthy individuals and patients with 
autoimmune diseases. This hypothesis has been verified by the clinical data of tocilizumab. The 
mean peak concentration of tocilizumab in patients with cytokine storms caused by CAR -T was 
41% lower than that in patients with systemic JIA, suggesting that tocilizumab was eliminated 
more rapidly in patients with cytokine storms (Le et al.,  2018). Therefore, sufficient exposure of 
TJ003234 will be required to effectivel y reduce GM -CSF levels and thus their downstream 
cytokine levels. Therefore, in order to better assess the dose response of TJ003234 in COVID -
19 severe patients, and determine an optimal dose for further development, we plan to include 
an additional dose l evel of 6  mg/kg TJ003234. Based on the PK from healthy adults, TJ003234 
PK appears to be linear and we expect that a single dose of 6  mg/kg may produce two -fold of 
drug exposure following a single dose of 3  mg/kg  TJ003234 , which will remain  within the range 
of drug exposure tested to be safe in the FIH.   
Overall, the totality of the data from the non -clinical data and clinical data from the single 
ascending dose escalation study supports 3 mg/kg and 6 mg/kg as safe dose s with potential 
efficacy to be ad ministered in COVID -19 patients. Furthermore, the observed efficacy, safety, 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  46  
 and PK data in the completed Part 2 Phase 2 study  support a single dose of 10 mg/kg TJ003234 
in the subsequent Part 2 Phase 3 trial as a safe dose with potentially further improve d efficacy.  
3.4. Criteria for T ermination of Study  
During the conduct of the study, if the investigator or the sponsor finds that continuation of the 
trial may cause potential harm to subjects, or the study is futile per IDMC ’s assessment , the 
decision may be made to terminate the trial after consultation between the investigator, medical 
monitor and the sponsor.  
4. Selection of Study Populations  
4.1.  Inclusion Criteria  
1. Age: 18 years or older (including 18 years); male or female  
2. Laboratory -confirmed SARS -COV -2 or COVID -19 infection as determined by polymerase 
chain reaction (PCR) or other commercial or public health assay.  
3. Bilateral lung infection confirmed by imaging  
4. Severe disease that meets one of the following conditions:  
i. At rest, finger blood oxygen saturation ≤ 93% or PaO2/FiO2 ≤ 300 mmHg; OR  
ii. Requiring high flow oxygen ≥ 15L/min  
5. Subjects or LARs who are willing to participate in this study and sign the informed consent 
voluntarily.  
6. Be willing to follow the contraception guidelines in Appendix 1  
7. Subje ct has been hospitalized for no more than 5 calendar days at the time of screening.  
4.2. Exclusion Criteria  
1. Any previous and/or current clinically significant disease or condition that has not been stable 
within 3 months prior to enrollment, or acute illness, planned medical/ surgical procedure, or 
any trauma that occurred within 2 weeks prior to enrollment, which, in the opinion of the 
investigator, may place the subject at risk if participating in the study, or may interfere with 
the assessment of the study d rug or confound interpretation of the study results, or affect the 
patient's ability to participate in the study independently.  
2. Applies to Part 1 only: Chronic obstructive pulmonary disease (COPD) and moderate/severe 
asthmatic patients requiring inhaled corticosteroid, long -acting beta -adrenergic agonists, 
long-acting anticholinergics, or long -term oxygen therapy. Mild asthmatic patients treated 
with shor t-acting beta -adrenergic agonists and/or low dose of inhaled corticosteroid and/or 
long-acting beta -adrenergic agonists are considered eligible. Please refer to Appendix 4 for 
inhaled cortiscoteroids dose guidance.  
3. Pulmonary interstitial disease, pulmonary  alveolar proteinosis, and pulmonary 
granulomatosis.  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  47  
 4. Cardiovascular event  in the 3 months prior to study drug administration : acute myocardial 
infarction or unstable angina pectoris, severe arrhythmia (multiple sources of frequent 
ventricular premature bea t, ventricular tachycardia and ventricular fibrillation); New York 
Heart Association Classification (NYHA): Class III -Class IV .  
5. Severe renal impairment: e.g.  eGFR ≤30 ml/min  estimated by  MDRD  equation  or have 
received treatments such as kidney transplantat ion and dialysis.  
6. Subjects that cannot adhere to protocol requirements due to neuropsychiatric disorder s. 
7. Severe liver disease: e.g.  Child -Pugh Score for Cirrhosis as (Grade C, elevated aspartate 
aminotransferase (AST) or alanine aminotransferase (ALT) (> 5 × upper limit of normal.  
8. Known active or chronic hepatitis B or C infection or human immunodeficiency virus (HIV) . 
9. Known active tuberculosis (TB), history of incompletely treated TB, suspected or known 
extrapulmonary TB, suspected or known systemic bacterial or fungal infections . 
10. Blood system disorders or routine blood analysis test abnormalities:  
 Hemoglobin < 8 g/dL;  
 ANC  <1500  × 109/L; 
 Platelets < 50 × 109/L. 
11. Dependence on glucocorticoid treatment equivalent to methylprednisolone 2 mg/kg/ day or 
more or long -term use of anti -rejection or immunomodulatory drugs.  
12. Subjects that require invasive mechanical ventilation or ECMO.  
13. Pregnant  or breastfeeding females.  
14. Have received any live vaccination within 30 days before dosing.  
15. Subjects who, in the opinion of the investigator, are not suitable for participation in this 
clinical study  or will not agree to follow the institution ’s supportive  care protocol . Any 
condition that, in the opinion of the investigator, may increase the risk associated with the 
subject's participation in the study or may interfere with the assessment of the study drug or 
confound the interpretation of the study result s.  
4.3. Subject Numbering  
Three -digit subject numbers will be allocated as all subjects consent to take part in the study. 
Subject numbers in Part 1 will follow the pattern “1yy”. Subject numbers in Part 2 will follow 
the pattern with “2yy” and “3yy”. Within each study site, this number will be allocated to subjects 
according to the sequence of presentation for trial participation. The subject number will be 
combined with the 4 -digit site number (“xxxx ”) to form the unique 7 -digit subject identifier 
(“xxxx -1yy” for subjects in Part 1 and “xxxx -2yy” for subjects in Part 2  Phase 2 and “xxxx -3yy” 
for subjects in Part 2 Phase 3 ) for the study. This subject ID number will also be used as a unique 
identifier for the subject throughout the study for lab reports, source, safety reporting forms, case 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  48  
 report forms ( CRFs ), etc.  
4.4. Withdrawal Criteria   
A subject is free to withdraw from the study at any time. In addition, a subject will be withdrawn 
if any of the following criteria are met:  
1) Subject withdraw s informed consent  
2) Subject is lost to follow -up after the investigator or designee has made multiple 
documented attempts to regain co ntact with the subject , including at least  two attempts 
by telephone  and a final attempt by certified or traceable mail.  
Prior to withdrawal, subjects should be encouraged to complete all follow -up assessments if 
possible . Subjects with ongoing adverse eve nts at the time of withdrawal should be followed in 
accordance with Section 7.1.5 .   
5. Study drug  
The study drug , TJ003234 , is provided by I -Mab Biopharma Co., Ltd., and should  only be used 
for th is study according to the study protocol  and Pharmacy Manual . Placebo  will be 0.9% 
sodium chloride injection (normal saline ) and must be provided by the site.  
5.1. Physical and chemical properties, specifications and ingredients  of drugs     
TJ003234 is a recombinant anti -GM-CSF humanized monoclonal antibody, consisting of two 
heavy chains and two light chains of IgG1. Each heavy chain contains 450 amino acids and each 
light chain contains 214 amino acids. Its theoretical molecular weight is a bout 146 kDa.  
TJ003234 is a brown -yellow sterile liquid , with a specification of 200 mg/2 ml/ vial. Its 
ingredients contain 100 mg/ml TJ003234, 0.96 mg/ml L -histidine, and 2.89 mg/ml L -histidine 
hydrochloride, 75.31 mg/ml sucrose, 0.2 mg/ml polysorbate 80  (pH 5.8).  
The drug TJ003234 should be stored and transported at 2 -8°C, protected from light .  
5.2. Drug Packaging , Labelling , and Storage   
TJ003234 drug product is packaged in a 2 ml type I glass vial, stoppered with 13 mm  bromobutyl 
rubber stopper (Aptar Ste lmi) and capped with aluminum cap. Vials  of TJ003234 will be  
packaged in cartons. Each vial and carton will contain a label stating the study number,  lot 
number, date of manufacture, drug type, storage conditions, and appropriate precautionary 
statements.  
The Investigator or designee must confirm appropriate temperature conditions have been  
maintained during transit for all study treatment received and any discrepancies are reported 
and resolved before use of the study treatment.  
All study treatments must b e stored in a secure, environmentally controlled  area in accordance 
with the labeled storage conditions with access limited to the Investigator and authorized 
clinical center staff.  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  49  
 5.3. Drug Dispensing, Administration and Dosage  
5.3.1.  Randomization and Bli nding  
Both parts of this study are randomized, double -blind, and placebo controlled . 
Most study personnel will remain blinded for the duration of each Part of the study  (i.e., Part 1 
will remain blinded until the completion of Part 1 , at which point it will be unblinded for 
exploratory analyses ; Part 2 phase 2 will remain blinded until com pletion of Part 2 phase 2 ; and 
Part 2 phase 3 will remain blinded  until database lock) . To allow for the execution of clinical 
trial-related services,  the following individuals will be unblinded during the study:  
 External randomization and trial supply management ( RTSM ) vendor  
 Independent Statistician  
 External clinical supply distribution vendor  
 Bioanalytical laboratory analyst  
 Sponsor Drug Supply Management Representative  
 Site pharmacy staff  
 Unblinded study nurse (if needed for  site operations to administer study drug)  
5.3.1.1.  Part 1  
There will be approximately 24 subjects randomized 1:1:1  (eight  3 mg/kg TJ003234: eight  6 
mg/kg TJ003234: eight  placebo) to the following treatment arms : 
 Treatment 1A: TJ003234 3 mg/kg (initial dose assignment based on weight at screening); 
single dose.  
 Treatment 1B: TJ003234 6 mg/kg (initial dose assignment based on weight at screening); 
single dose.  
 Treatment 1C: Placebo  (administered as normal saline) ; single dose.  
Randomization will not be stratified. Each investigational site will randomize subjects to 
treatment groups using a randomization scheme generated by an RTSM system. Treatment 
allocation will be blinded per Section 5.3.1.   
After the safety evaluation  and decision has been made  to continue to Part 2 , the data from Part 
1 will be  analyzed for exploratory analysis.  
5.3.1.2.  Part 2  
There will be approximately 570 subjects randomized 2:1 (380 TJ003234: 190 placebo)  to the  
following treatments arms:  
 Treatment 2A: TJ003234 6 mg/kg ( phase 2) or 10 mg/kg (phase 3), with initial dose 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  50  
 assignment based on weight at screening; single dose.  
 Treatment 2B: Placebo , administered as normal saline ; single dose.  
Randomization will be str atified  by age  at randomization  (<60 years  versus  ≥ 60 years ) use of 
remdesivir (yes versus no ). Each investigational site will randomize subjects to treatment groups 
using a randomization scheme generated by an RTSM system.  For more information, please refer 
to the Pharmacy Manual. Treatment allocation will be blinded per Section 5.3.1.  
5.3.2.  Drug Dispensing  
Once the treatment assignment has been confirmed per Section 5.3.1.1 or Section 5.3.1.2 , if the 
subjects is assigned to a T J003234 treatment ar m, the study drug  dose will be  calculated 
according to the body weight of subjects at screening  when dispensing. The study drug  is diluted 
to appropriate volume and concentration with 0.9% sodium chloride injection (normal saline) 
(see Table 4). After dilution with normal saline in the infusion bag, diluted study drug should be 
fully infused within 4 hours if stored at room temperature, or within 24 h ours if stored at 2 -8℃. 
If the subject is  assigned to a placebo arm, normal saline will be administered per the Pharmacy 
Manual . 
Table 4. Study drug dispensing dose and volume  
 
For specific instructions on the preparation and management of the study drug , refer to the 
Pharmacy Manual .  
5.3.3.  Drug Administration  
After pre-dose procedures have been conducted on Day 1, eligible subjects will receive a single 
dose of their assigned treatment , diluted using normal saline (0.9% NaCl) to the appropriate 
volume and concentration per Table 4 and the subject ’s body weight at screening. Administer 
using a low -protein -binding 0. 22 μm in-line filter and an infusion pump. The infusion line should 
be flushed with 0.9% sodium chloride injection after TJ003234 administration to ensure that the 
subject  receives the full dose. All doses should be administered over 1 hour. Further instructions 
with details on handling and administration of study drug is described in the separate Pharmacy 
Manual.  
5.4. Compliance Requirements  
5.4.1.  Contraceptive requirements  
Females of childbearing potential and males should agree to take appropriate contraceptive Subject weight  Dosing mode  Infusion bag  Specification and total 
volume of infusion bag   
≤ 100 kg  Intravenous drip  Infusion bags  100 mL  
100.1 to 250  kg Intravenous drip  Infusion bags  250mL  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  51  
 measures during the trial period and for 4 months after the final dose of study drug. For detailed 
instructions and definitions, please refer to Appendix 1.  
5.5. Concomi tant Medication and Therapies  
The investigator should record all concomitant medications  (including any investigational 
therapies) , indications, daily doses, starting and ending dates of dosing throughout the study.  
Medications and therapies administered  within 3 days of the first dose of study drug  (with the 
exception of SARS -CoV-2 vaccine history)  should be  recorded as prior medications  or therapies . 
Medications or therapies  received after the first dosing of the study drug should be  recorded as 
concomitant medication s or therapies .  
5.6. Prohibited Medications  
The following prior or concomitant medications are not allowed during the trial:  
1. Immunomodulatory/immunosuppressive drugs, including biologics and JAK inhibitors 
except when admini stered as a rescue therapy as described in Section 5.7   (Note: 
recommended drugs for standard treatment are allowed, such as Glucocorticoid ). 
2. Drugs that may aggravate the subject s’ conditions per the investigator ’s judgement .  
3. Any vaccine  during the trial or any live vaccine within 30 days prior to dosing , with the 
exception of the SARS -CoV-2 vaccine.      
5.7. Rescue Therapies  
Rescue therapies are considered to be any otherwise prohibited medications given for COVID -
19 (e.g. convalescent plasma, tocilizumab , etc.)  that are administered after the subject has 
received the study drug and experiences deterioration in their  clinical condition . Rescue therapies 
are permitted  after study drug administration at the Investigator ’s discretion  and a deterioration 
of clinical status must be documented . Prior to administering a rescue therapy , perform the 
following procedures as an unscheduled visit:  
 Clinical Status Assessment  
 Arterial Blood Gas Analysis  
 SOFA Score  
 PaO2/FiO2 ratio  
 Physical Examination  
 Pulse Oximetry  
 Vital Signs  
 Clinical Laboratory Tests: CBC, Serum Biochemistry, Troponin, CRP, LDH, Ferritin, 
Cytokine Levels  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  52  
 6. Study Procedure s   
This trial will use a 2-part randomized, double -blind , placebo -controlled  design and observation 
for 30 days after a single dose  of study drug . The study procedure s are described below.  
6.1. Description of Study Procedures  
6.1.1.  Vital signs  and Pulse Oximetry  
The following vital signs will be measured according to the schedule of procedures: temperature, 
pulse, respiratory rate and blood pressure.  
Vital signs should be monitored and recorded within 30 min before drug infusion, 30 min ± 5 
min after the start of  infusion , at the end of infusion  ± 5 min, and 60 min ± 5 min after infusion.  
The measurement of blood pressure and pulse should occur  according to institutional practices.   
Pulse oximetry should be recorded daily while hospitalized . The lowest registered  level from 
each day should be collected.  
6.1.2.  Physical examination  
A general physical examination should include the overall appearance , head and face, ear, nose , 
throat, mouth, skin, lymph nodes, respiratory, cardiovascular, abdomen, urogenital (when 
necessar y), musculoskeletal and nervous, and neurological systems . Missed body systems will 
not be considered a protocol deviation, unless there are  ongoing Adverse Events that are not 
assessed as a result of missed body systems.  
6.1.3.  ECG   
ECG s will be performed as sp ecified in the schedule of procedures  according to institutional 
practices .  
During visits where both ECGs and blood draws are scheduled, the ECG should take place before 
the blood draws.  
6.1.4.  Clinical laboratory tests  
Blood samples will be collected for serum biochemical and hematological analysis. Urine 
samples will be collected for urinalysis. The investigator shall review the laboratory test results 
and record laboratory test results with clinical significance as jud ged by the investigator as an 
adverse event .  
Table 5. Laboratory Tests  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  53  
 Serum 
biochemical 
test  • Blood glucose  
• Liver and kidney functions: Alanine aminotransferase, aspartate aminotransferase, 
alkaline phosphatase, γ-glutamyltransferas e, total protein, albumin, total bilirubin, 
direct bilirubin, creatinine, eGFRa, BUN , uric acid.  
• Serum electrolytes: potassium, sodium, chlorine, calcium, magnesium, inorganic 
phosphorus.  
CBC  • White blood cells, absolute neutrophil count and percentage, absolute lymphocyte 
count and percentage, absolute monocyte count and percentage, absolute e osinophil 
count and percentage, absolute basophil count and percentage.  
• Red blood cells, hemoglobin, hematocrit, mean cell volume  
• Platelets  
Coagulation 
assessment  • Prothrombin time, International Normalized Ratio  
• Activated partial thromboplastin time  
• D-dimer  
Urinalysis  • Bilirubin, Blood, Color and appearance, Glucose, Ketones, Leukocyte esterase, Nitrite, 
pH, Protein, Specific gravity, Urobilinogen  
• Microscopic examination (if protein, leukocyte esterase, nitrite, or blood is positive)  
Other  • β-human chorionic gonadotropin b 
• Follicle -stimulating Hormone  (FSH)  test c 
• Inflammation -related indicators: troponin, C -reactive protein, LDH, serum ferritin  
• Arterial blood gas analysis: pH, partial pressure of oxygen, partial pressure of carbon 
dioxid e, total carbon dioxide, oxygen saturation, actual bicarbonate, standard 
bicarbonate, base excess, anion gap  
• SARS -CoV-2 diagnostic test by PCR or other commercia l or public health assay . Note 
that a standardized method should be used for collection of nasopharyngeal samples.  
Please use the same nostril for collections if only one nostril will be sampled . 
• Cytokines, such as IL-1RA, IL -1β, IL-2, IL -6, IL -7, IL -10, G CSF, GM -CSF, CCL2, 
CCL3, CCL17,  CXCL10, TNF -α and IFN -γ 
• Pharmacokinetic Sampling (for those in the PK/ADA subgroup in Part 2)  
• ADA Sampling (for those in the PK/ADA subgroup in Part 2)  
a. eGFR(ml/min×1.73m2) =175×creatinine ([Scr(mg/dL)])-1.154×age-0.203×gender ( male=1, female =0.742) ×1.212 (if black)  ; 
b. Serum  pregnancy test for women of childbearing potential at the time of screening.  
c. If needed to confirm menopausal status.  
6.1.5.  Radiographic L ung Imaging  
Radiographic l ung imaging include s lung CT or chest X -ray. If this procedure was performed as 
standard of care in the 14 days prior to Day 1 and radiographic infiltrates are present, this may 
be used,  and imaging is not required at Screening or Day 1.       
6.1.6.  Pregnancy test  
A blood pregnancy test will be performed for women of childbearing potential at screening . 
Pregnant women are not eligible to participate in this study and will be considered ineligible for 
screening.    
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  54  
 6.1.7.  Adverse Events (AEs)  
The investigator should collect and record AEs for each subject from the signing of the informed 
consent to 30 days after the last dose. The investigator is responsible for observation, recording 
and follow -up of all AEs that occur during the study, regardless of any cause. Serious adverse 
events (SAE s) that occur within 30 days after the last dose should also be collected and reported 
if considered as related to TJ003234 by investigator  (see Section 7.2.3 for the reporting process). 
The investigator will follow up AEs as specified in Section 7.  
6.2. Scree ning period (Day -3 to Day -1)  
Subjects (or LAR) should sign a written or electronic ICF on a voluntary basis before screening. 
The screening is performed within D ay -3 to D ay -1, to identify if they meet the 
inclusion/exclusion criteria. Those subjects who meet all inclusion criteria and do not meet any 
one of the exclusion criteria are eligible to participate in this trial. The screening procedures 
include the following:  
 Demog raphic data (including gender, age, ethnicity, date of birth);  
 Height and body weight;  
 Medical history  from previous 5 years , including smoking history . Ensure that the date 
of onset of COVID -19 symptoms is recorded as part of the Medical History ;  
 SARS -CoV -2 vaccine history (not restrictive to within 3 days before dosing);  
o Number of doses  
o Date of dose(s)  
o Brand name  
 Collecting a complete history of prescription or over -the-counter drugs , dietary 
supplements and herbal medicines used within 3 days bef ore dosing;  
 Physical examination ; 
 12-lead ECG ; 
 Vital signs;  
 PaO2 /FiO2 ratio;  
 Radiographic  lung imaging (chest x -ray or CT ) (see section 6.1.5) ;  
 Biological samples  are collected for the following tests . If any of these labs were drawn 
prior to subject signing consent , but within 72 hours of dosing , they may be used  for the 
purposes of this visit and they do not need to be repeated :  
o Safety laboratory tests (CBC , blood biochemistry test , urinalysis ); 
o Coagulation function test (prothrombin time (PT), acti vated partial prothrombin 
time (APTT), international normalized ratio , D-dimer );   
o Blood β -HCG testing (required for female subjects of childbearing potential only) ;  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  55  
 o FSH test (to confirm menopausal status, if applicable)  
o Testing of C -Reactive Protein  (CRP) , Lactate Dehydrogenase (LDH)  and serum 
ferritin ;  
o SARS -CoV -2 diagnostic test by PCR or other commercial or public health assay . 
If a subject has a positive test within the 14 days prior to study drug administration, 
this may be used to assess eligibility, and an additional test at screening does not 
need to be performed.  Note that a standardized method should be used for collection 
of nasopharyngeal samples. Please use the same nostril for collections if only one 
nostril will be sampled.  
o Arteri al blood gas analysis ; 
o Testing of cytokine level s.  
 Pulse oximetry ;  
 Collection/evaluation of adverse events at baseline.  
 Review subject eligibility  
6.3. Baseline period (Day 1)  
Subjects will complete the following procedures before dosing:  
 Review any changes in subject’s status  since screening to confirm eligibility;  
 Physical examination ; 
 Biological  samples are collected for the following tests:    
o Safety l aboratory tests (routine blood analysis, blood biochemistry test , urinalysis ); 
o Coagulation function test  (PT, aPTT, INR , D-dimer ); 
o Arterial blood gas analysis  (may be omitted if screening test was done  within 24 
hours ); 
o Troponin test;  
o Testing of CRP,  LDH and serum ferritin ; 
o Testing of cytokine level s. 
o PK and ADA sampling (if included in the PK/ADA subgroup in Part 2)  
 Vital signs ; 
 PaO2/FiO2 ratio;  
 12-lead ECG ; 
 Pulse oximetry ; 
 Record b aseline respiratory  support  requirements (e.g., oxygen requirements)  
 Clinical status assessment ; 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  56  
  SOFA score . 
If dosing occurs within 24 hours of screening, pre -dose procedures do  not need to be repeated, 
unless the labs are from within >24 hours of dosing. The following procedures must be 
completed Predose, as they were not completed as screening assessments : 
 SOFA score  
 Clinical Assessment  
 Troponin test  
After completing the above procedures, subjects will be randomized and receive their assigned 
study drug by IV infusion .  
During the infusion, vital signs will be measured in accordance with Section 6.1.1. After end of  
infusion, the following procedures will be performed :  
 Vital signs ;  
 12-lead ECG ; 
 Collection/evaluation of adverse events ; 
 Monitoring concomitant medication/treatment . 
After the infusion, the following procedure will be performed within 15 minutes of end of 
infusion:  
 PK sampling (for those subjects in the PK/ADA subgroup in Part 2)  
6.4. Follow -up period: Day 2  
The following procedures will be performed :  
 Vital signs ;  
 Physical Examination;  
 Biological  samples are collected for the following tests:    
o Safety l aboratory tests (routine blood analysis, blood biochemistry test, urinalysis ); 
o Coagulation function test ( PT, aPTT, INR , D-dimer ); 
o Testing of CRP,  LDH and serum ferritin ; 
o Testing of cytokine level s. 
 Pulse oximetry  
 Collection/evaluation of adverse events ; 
 Monitoring concomitant medication/treatment . 
6.5. Follow -up period: Day 3  
The following procedures will be performed   
 Vital signs ; 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  57  
  Physical Examination;  
 Biological  samples are collected for the following tests:    
o Safety l aboratory tests (routine blood analysis, blood biochemistry tes t, urinalysis ); 
o Coagulation fun ction test (PT, aPTT, INR , D-dimer ); 
o Testing of CRP,  LDH and serum ferritin ; 
o Testing of cytokine level s. 
 Pulse oximetry  
 Collection/evaluation of adverse event s 
 Monitoring concomitant medication/treatment  
6.6. Follow -up period: Day 5  
The following procedures will be performed :  
 Vital signs ; 
 Physical Examination;  
 Biological  samples are collected for the following tests:    
o Safety l aboratory tests (routine blood analysis, blood biochemistry test , urinalysis ); 
o Coagulation function test ( PT, aPTT, INR , D-dimer ); 
o Testing of CRP,  LDH and serum ferritin ; 
o Testing of cytokine level s. 
 Pulse oximetry  
 Collection/evaluation of adverse event s 
 Monitoring concomitant medication/treatment  
6.7. Follow -up period: Day 7  
If subjects are discharged prior to this visit, the visit may occur as an outpatient or 
telephone visit. If the visit occurs via telephone, only collection/evaluation of adverse 
events, clinical status assessment (including whether subject is still on supp lemental 
oxygen support), and monitoring concomitant medication and treatment must occur. The 
following procedures will be performed:  
 Vital signs ; 
 Physical Examination;  
 Biological  samples are collected for the following tests:    
o Safety l aboratory tests (routine blood analysis, blood biochemistry test , urinalysis ); 
o Coagulation function test (PT, aPTT, INR , D-dimer ); 
o Arterial blood gas analysi s (not needed if conducted as an outpatient visit) ; 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  58  
 o Troponin test;  
o Testing of CRP, LDH and serum ferritin ; 
o SARS -CoV -2 diagnostic test by PCR or other commercial or public health assay  
o Testing of cytokine level . 
o PK sampling (for those subjects in the PK/ADA subgroup in Part 2)  
 12-lead ECG ; 
 PaO2/FiO2 ratio  (not needed if conducted as an outpatient visit ) 
 Pulse oximetry  
 Radio graphic  Lung Imaging;  
 Clinical status assessment ; 
 SOFA score  (not needed if conducted as an outpatient visit) ; 
 Collection/evaluation of adverse events ; 
 Monitoring concomitant medication/treatment . 
6.8. Follow -up period: Day 11 ± 1  
If subjects are discharged prior to this visit, this visit may occur via telephone. If the visit 
occurs via telephone, only collection/evaluation of adverse events, and monitoring 
concomitant medication and treatment must occur. Otherwise, t he following pr ocedures 
will be performed :  
 Vital signs;  
 Pulse oximetry;  
 Collection/evaluation of adverse event  
 Monitoring concomitant medication/treatment  
6.9. Follow -up period: Day 14 ± 2  
If subjects are discharged prior to this visit, the visit may occur as an outpatient or telephone 
visit. If the visit occurs via telephone, only collection/evaluation of adverse events, clinical 
status assessment (including whether subject is still on supplemental oxygen support), and 
monitoring concomitant medication and treatment must oc cur. The following procedures 
will be performed:  
 Vital signs ; 
 Physical Examination;  
 Biological  samples are collected for the following tests:    
o Safety l aboratory tests (routine blood analysis, blood biochemistry test , urinalysis ); 
o Coagulation function test (PT , aPTT, INR, D-dimer ); 
o Arterial blood gas analysi s; (not needed if performed as an outpatient visit) ; 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  59  
 o Troponin test;  
o Testing of CRP, LDH and serum ferritin ; 
o SARS -CoV -2 diagnostic test by PCR or other commercial or public health assay  
o Testing of cytokine level s 
o PK and ADA sampling (if included in the PK/ADA subgroup in Part 2)  
 12-lead ECG ; 
 PaO2/FiO2 ratio  (not needed if conducted as an outpatient visit)  
 Pulse oximetry  
 Radio graphic  lung imaging;  
 Clinical status assessment ; 
 SOFA score  (not needed i f conducted as an outpatient visit) ; 
 Collection/evaluation of adverse events ; 
 Monitoring concomitant medication/treatment . 
6.10. Follow -up period: Day 30± 2 (End of Study Visit)  
If subjects are discharged prior to this visit, this visit may occur as an outpatient visit or via 
telephone. If the visit occurs via telephone, only collection/evaluation of adverse events, clinical 
status assessment  (including whethe r subject is still on supplemental oxygen support) , and 
monitoring concomitant medication and treatment must occur. Otherwise, t he following 
procedures will be performed:  
 Vital signs ; 
 Physical Examination;  
 Biological  samples are collected for the following tests:    
o Safety l aboratory tests (routine blood analysis, blood biochemistry test , urinalysis ); 
o Coagulation function test (PT, aPTT, INR, D-dimer ); 
o Arterial blood gas analysi s (not needed if conducted as an outpatient visit) ; 
o Testing of CRP, LDH and serum ferritin ; 
o SARS -CoV -2 diagnostic test by PCR or other commercial or public health assay  
o Testing of cytokine level s. 
 12-lead ECG ; 
 PaO2/FiO2 ratio  (not needed if conducted as an outpatient visit) ; 
 Pulse oximetry ; 
 Radio graphic  lung imaging;  
 Clinical status assessment ; 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  60  
  SOFA score  (not needed if conducted as an outpatient visit) ; 
 Collection/evaluation of adverse events ; 
 Monitoring concomitant medication/treatment . 
6.11. Discharge from Hospital  
If a subject is discharged from the hospital prior to the end of study visit, an unscheduled arterial 
blood gas analysis , PaO2/FiO2 ratio,  and a SOFA score should be completed based on the last 
arterial blood gas analysis performed while the subject was hospitalized.  
7. Safety and Reporting  
7.1. Adverse Events  
Adverse events observed or discovered by the Investigator or those reported by subjects, 
regardless of having a suspicious causal relationship with the study drug or not, must be re corded 
according to the following requirements.  
7.1.1.  Definition of Adverse Events  
An adverse event (AE) is defined as any reaction, side effect, or untoward event that occurs 
during the course of the clinical trial whether or not the event is considered related to the study 
drug. Disease progression or deterioration must also be  recorded as an AE/SAE , regardless of 
whether the Investigator assesses that it is related to the study drug . Additionally, signs and 
symptoms from the following may be considered AEs: drug overdose, withdrawal or misuse, 
drug interactions, extravasations, exposure during pregnancy/breastfeeding.  
7.1.2.  Collection of Adverse Events  
The Investigator shoul d report all adverse events using concise medical terminologies.  Disease 
diagnosis should be given as much as possible rather than listing symptoms and signs only.   
The Investigator should collect and record adverse events for all subjects from the signing  of the 
informed consent to 30 days after the last dose  or the subject meets the withdrawal criteria in 
Section 4.4 . The Investigator is responsible for observation, recording and follow -up of all 
adverse events that occur during the study, regardless of a ny cause. SAEs that occur after 30 days 
of the last dose or after a withdrawal criteria is met  should also be collected and reported (see 
7.2.4 for the reporting process) if judged to be possibly related to the study drug by the 
investigator.   
For any adverse event that occurs during this trial, regardless of seriousness and relatedness , the 
Investigator should record them in the CRF, including the occurrence date, symptoms, severity 
(CTCAE), even start and stop dates, action taken with the stud y drug (no action taken, stopped 
temporarily, permanently discontinued or N/A), treatment methods and outcomes (resolved, 
resolved with sequelae, not resolved, resolving, fatal, or unknown), etc. In addition, based on a 
comprehensive consideration of the d isease itself, comorbidities, and concomitant 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  61  
 medications/therapies, its causal relationship with the study drug should be evaluated.  
The Investigator should determine whether the abnormal laboratory test result is clinically 
significant or not. If the ab normal laboratory test value is clinically significant, it should be 
recorded as an adverse event on the original medical records and CRFs.   
If unexplainable, abnormal laboratory test results occur, repeated tests or follow up should be 
performed until th e test results are within the normal range or at the baseline level and/or the 
abnormal results are reasonably and adequately explained and recorded on the original medical 
records and CRFs.  
If any new infections occur regardless of the infection agent (i .e., viral or non -viral), they should 
be recorded as AEs . Additionally, in the CRF, the site of infection and source of culture 
(bronchoalveolar lavage , tracheal aspirate, sputum, blood, urine, etc.,) should also be recorded.   
7.1.3.  Criteria for severity of adve rse events  
The severity of adverse events is judged per CTCAE version 5.0 standard, divided into the 
following 5 grades:  
 Grade 1 - Mild, requiring no treatment or requiring minimal, non -invasive treatment 
only.  
 Grade 2 - Moderate, requiring a general degree  of non -invasive treatment.  
 Grade 3 - Serious, resulting in limited daily activities.  
 Grade 4 - Symptoms that may be life -threatening, leading to limited daily activities, or 
permanent injury and disability.  
 Grade 5 - Death.  
7.1.4.  Criteria for determining causalit y between adverse events and study drug  
The investigator will determine the causality between adverse events and the study drug 
according to the correlation between them, and divide them into five categories, they are 
“definitely related, probably related, possibly related, unlikely related, def initely unrelated ”. 
“Definitely related, probably related, and possibly related ” are classified into related to the study 
drug, and “unlikely related, definitely unrelated ” are classified into unrelated to the study drug.   
 Definitely unrelated   
AE is def initely not related to the use of study drug.  
  Unlikely related  
AE is more likely to be caused by other factors such as concomitant medications or concomitant 
disease, or the temporal relationship indicates that it is unlikely to be causally related to th e study 
drug.   
 Possibly related  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  62  
 AE may be related to the study drug . Other factors such as concomitant medications or 
concomitant disease have not been identified yet. There is a reasonable temporal  relationship 
between the AE and study drug; therefore, a causal relationship is not ruled out.  
 Probably related  
AE may be related to the drug use. There is indicative temporal  relationship (for example, 
determined by study drug discontinuance). It is unlikely to be caused by other factors such as 
concomitant medications or concomitant disease.   
 Definitely related  
AE is a possible adverse reaction and cannot be explained by other reasons, such as concomitant 
medications and concomitant disease. There is an obvious temporal  relationship between the AE 
and the study drug  (for example, it can be determined by study drug discontinuance and 
rechallenge ).    
7.1.5.  Follow -up of Adverse Events  
All adverse events (including abnormal laborat ory test results) must be followed up until the end 
of the study or any one of the following conditions has been achieved , whichever occurs later : 
 The event has resolved ;  
 The event is stable;  
 The event returns to the baseline level;  
 The event is judged as not treatment -related by investigator;  
 When more information is not available (subject withdrew consent and/or refuse s to 
provide more information, is lost to follow up or dies);  
 The investigator  determines that  further follow -up is not warranted .   
7.2. Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESI)  
7.2.1.  Definition of SAE  
An AE that meets any one of the following conditions, regardless of whether related to study 
drug or not, should be considered a serious adv erse event:  
1) Results in death;  
2) Is life-threatening ( i.e., the subject was at immediate risk of death from the adverse event 
as it occurred; this does not include an event that, had it occurred in a more severe form 
or was allowed to continue, might h ave caused death );  
      3) Causes inpatient hospitalization or prolongation of existing hospitalization;  
4) Results in persistent or significant disability/incapacity ; 
5) Is a congenital anomal y or birth defect  (in the child of a subject who was exposed to the 
study drug) ;  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  63  
 Other important medical events that may not be immediately life -threatening or result in death 
or hospitalization but, when based on appropriate medical judgment, may jeopardize the subject 
or may require intervention to prevent one of the outcomes in the definition of SAE listed above 
should also be considered SAEs.  Medical and scientific judgment should be exercised in 
deciding whether expedited reporting is appropriate in such situations.    
The following hospitalizations are not considered to be SAEs because there is no “adverse event ” 
(i.e., there is no untoward medical occurrence) associated with the hospitalized:  
 Hospitalizations for respite care  
 Planned hospitalizations required by the protocol  
 Hospitalizations planned before informed consent (where the condition requiring the 
hospitalization has not changed post study drug administration)  
 Hospitalization for routine maintenance of a device (e.g., battery replacement) that was 
in place before study entry  
7.2.2.  Adverse Event of Special Interest (AESI)  
This study will consider the following AEs to be AESIs:  
 Infusion -related reactions at grade 3 or higher  
 Grade 3 or higher infections  
 Pulmonary alveolar proteinosis.  
These AESIs may not meet the  criteria of an SAE, but the investigator shall report them 
according to the reporting requirements and timeframe of SAEs (i.e., the investigator shall fill 
out the  Serious Adverse Event Report Form as soon as possible (within 24 hours) after becoming 
awar e of the AESI, and follow up the outcome of the event. If the IRB has any reporting 
requirements for the AESI, the investigator shall report them in accordance with relevant IRB 
requirements (if applicable).    
7.2.3.  Reporting of SAE s and AESI s  
Any SAE or AESI,  which occurs to any subject participating in this study must be reported by 
investigator to the sponsor within 24 hours (and IRB as required) of first becoming aware of the 
event. The study sponsor will be responsible for notifying the FDA of any unexpect ed fatal or 
life-threatening suspected adverse reaction as soon as possible, but in no later than 7 calendar 
days after the sponsor's initial receipt of the information. In addition, the sponsor must notify 
FDA and all participating investigators in an IND  safety report of potential serious risks, from 
clinical trials or any other source, as soon as possible, but in no later than 15 calendar days after 
the sponsor determines that the information qualifies for reporting.  
SAEs will be collected by the investigator from the time of consent through 30 days after the last 
dose of study drug  or the subject meets the withdrawal criteria in Section 4.4 . Any SAE that is 
judged by the investigator to be related to the study drug must be reported regardless of the 
amount of time since the last dose received. Follow -up information collected for any initial report 
of an SAE must also be reported to the spons or (or its designee) within 24 hours of receipt by 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  64  
 the investigator.  
In the event of death, regardless of cause, all attempts should be made to obtain the death 
certificate and any autopsy report, if performed. These records should be reviewed in detail, and 
the investigator should comment on any event, lab abnormality, or any other finding, noting 
whether it should be considered a serious or non -serious AE, or whether it should be considered 
as part of the subject ’s history. In addition, all events or oth er findings determined to be SAEs 
should be identified on the follow -up SAE form and the investigator should consider whether 
the event is related or not related to study drug.  
7.3. Pregnancy  
A pregnancy event refers to pregnancy of a female subject or a male subject ’s partner during the 
trial. After becoming aware of the pregnancy, the investigator shall immediately fill out the 
Pregnancy Report Form , and promptly (within 24 hours after becoming aware of the pregnancy) 
report them to the sponsor or designee (a nd the IRB, if required). Pregnancy outcomes will be 
followed by the Sponsor. In addition, the investigator must report to the sponsor or designee 
follow -up information regarding the course of the pregnancy, including perinatal and neonatal 
outcome.   
7.4. Emerg ency  Unblinding  
As a double -blind , placebo -controlled study, both the subjects and Investigators are blinded to 
the study treatment assignment. In addition, it is anticipated that all clinical research personnel, 
laboratory personnel, except for personnel  needed to prepare the study drug, are  blinded  to the 
treatment assignment and will remain blinded through the completion of the study.  
In the event emergency unblinding of study treatment is necessary, the Investigator shall utilize 
the RTSM system to obtain subject dose details. The individual subject dose details should be 
revealed only in case of an emergency where the further treatment of the subject is dependent on 
knowing the study medication he or she has received. The date and tim e of breaking the blind as 
well as the reason must be recorded on the subject study medication record. The subject will be 
automatically discontinued from the study in the event emergency unblinding of study treatment 
takes place. If a blind is broken due to an adverse event, a corresponding adverse event entry 
must be completed in the CRF. Any ongoing AEs will be followed in accordance with Section 
7.1.5 of the protocol . 
It is strongly encouraged that unblinding only be completed after consultation with th e medical 
monitor, provided this does not compromise subject safety. If unblinding should occur (either by 
accident or for a medical emergency), the Investigator must promptly and immediately notify 
the Sponsor, study medical monitor, and IRB/IEC, and docu ment the circumstances surrounding 
this action in a memorandum to the study file.  
8. Data Handling and Recordkeeping  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  65  
 8.1. Data  Record and Management   
As used in this protocol, the term CRF should be understood to refer to either a paper form or an 
electronic data record or both, depending on the data collection method used in this study.  
A CRF is required and should be completed for each subject. The completed original CRFs are 
the sole property of I -Mab Biopharma and should not be made available in any form to third 
parties, except for authorized representatives of I -Mab Biopharma or appropriate regulatory 
authorities, without written permission from I -Mab Biopharma.  
The Investigator has ultimate responsibility for the collection and reporting of all clinical, safety, 
and laboratory data entered on the CRFs and any other data collection forms (source documents) 
and ensuring that they are accurate, authentic/original, attributable, complete, consistent, legible, 
timely (contemporaneous), enduring, and available w hen required. The CRFs must be signed by 
the Investigator or by an authorized staff member to attest that the data contained on the CRFs 
are true. Any corrections to entries made in the CRFs or source documents must be dated, 
initialed, and explained (if n ecessary) and should not obscure the original entry. In most cases, 
the source documents are the hospital's or the physician's patient chart. In these cases, data 
collected on the CRFs must match the data in those charts. Discrepancies in the data will be 
brought to the attention of the clinical team, and investigational site personnel, if necessary. 
Resolutions to these issues will be reflected in the database. An audit trail within the system will 
track all changes made to the data.   
8.2. Protocol Deviations   
The Investigator must adhere to the protocol as detailed in this document. The Investigator will 
be responsible for enrolling only those subjects who have met protocol eligibility criteria. The 
Investigators will be required to sign an Investigator Agreeme nt to confirm acceptance and 
willingness to comply with the study protocol. The Investigator should document and explain 
any protocol deviations in source. The Investigator should promptly report any deviations to 
the Sponsor or designee, and to the IRB/EC  in accordance with established IRB/EC policies 
and procedures. The Sponsor or designee will review all protocol deviations and conduct 
impact assessments as needed. As per the Sponsor's standard operating procedures, prospective 
requests to deviate from t he protocol, including requests to waive protocol eligibility criteria, 
are not allowed and will not be granted.  
8.3. Record Retention   
Essential documents must be retained by the Investigator for a minimum of 2 years after the last 
approv al of a marketing application in an International Conference on 
Harmonisation/International Council for Harmonisation (ICH) region and until there are no 
pending or contemplated marketing applications in an ICH region, or at least 2 years have 
elapsed sinc e the formal discontinuation of clinical development of the investigational product. 
The Investigator must retain these documents for the time period described above or according 
to local laws or requirements, whichever is longer. Essential documents inclu de, but are not 
limited to, the following:  signed informed consent documents for all subjects; subject 
identification code list, screening log (if applicable), and enrollment log; record of all 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  66  
 communications between the Investigator and the IRB; composit ion of the IRB; record of all 
communications between the Investigator, Sponsor, and their authorized representative(s); list of 
Sub investigators and other appropriately qualified persons to whom the Investigator has 
delegated significant study -related dut ies, together with their roles in the study, curriculum vitae, 
and their signatures; copies of CRFs (if paper) and of documentation of corrections for all 
subjects; investigational product accountability records; record of any body fluids or tissue 
samples  retained; and all other source documents (subject records, hospital records, laboratory 
records, etc.).
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  67  
 9. Statistical Considerations  
The details of the statistical methods and data presentation , PK and ADA analysis  will be 
provided in the Statistical Analysis Plan (SAP).   
 
9.1. Sample Size Determination  
This is a 2 -part study. Part 1 will enroll about 24 subjects to establish the safety of TJ003234 in 
subjects with severe COVID -19 before initiating Part 2.  
The estimate d rate of mechanical ventilation free subjects  in the c ontrol arm is based on recent 
observations in COVID -19 studies .  
The sample size of Part 2 Phase 2 portion is calculated based on the following assumptions:  
 Randomization ratio of 2:1  (TJ003234 6 mg/kg  : placebo);  
 Rate of  mechanical ventilations free subjects by Day 30:  88% in the  TJ003234 arm and 
77% in the placebo arm;  
 2-sided alpha of 0. 20 and 80% power.  
 10% drop out rate  
The sample size of Part 2 Phase 3 portion is calculated based on the following  assumptions:  
 Randomiz ation ratio of 2:1  (TJ003234 10 mg/kg : placebo );  
 Rate of  mechanical ventilations free subjects by Day 30: 88% in the  TJ003234  arm and 
77% in the placebo  arm; 
 2-sided alpha of 0.05 and 80% power.  
 10% drop out rate  
Part 2 plans to enroll of 570 subjects with 120 in the Phase 2 portion and  450 in the Phase 3 
portion . The results of Phase 2 portion may be used to re -estimate the sample size for Phase 3 
portion.  
 
9.2. General Considerations  
Analysis Populations :  
Intent -to-treat (ITT) Population: All randomized subjects . This population will be used for the  
primary analysis for Part 1 and Part 2 phase 2 portion, and sensitivity analysis of  primary  analysis  
for Part 2 phase 3 portion . 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  68  
  
Modified Intent -to-treat ( mITT) Population: All randomized subjects  who are non- mechanical 
ventila ted at baseline . This population will be used for the primary analysis  of Phase 2 phase 3 
portion .  
Safety Population: Includes all subjects who receive the study drug. This safety population will 
be used for the analysis of demographic data, baseline characteristics, and safety.  
Efficacy -evaluable Population: All subjects in the safety population with at least one post -dose 
efficacy evaluation.   
Methods for Statistical Analysis  
All data will be summariz ed by treatment group using descriptive statistics based on the data 
types  by timepoint if applicable.  Unless otherwise specified, descriptive statistics for continuous 
variables will include number of subjects, mean, standard deviation (SD), median, and range . 
For categorical variables, descriptive statistics including counts and percentages will be reported . 
All statistical analysis will be performed using SAS 9.4 (or above version) statistical analysis 
software. The specific statistical method will be d etailed in the Statistical Analysis Plan (SAP).  
9.3. Subject Demographics/Other Baseline Characteristics  
Demographics and baseline characteristics (age, sex, race, ethnicity, and some other baseline 
disease characteristics) will be summarized for the Safety Population. Descriptive statistics will 
be presented in addition to data listings.   
9.4. Safety Analysis  
Safety and tolerability evaluations will be performed for all subjects in the safety population.   
Unless otherwise specified, the last evaluation b efore do sing will be used as the baseline. AEs 
will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA).  
Summary statistics and listings of all the safety data will be provided by treatment group  and 
time points  as specified in the schedule of procedures . 
9.5. Efficacy Analysis  
All efficacy endpoints will be summarized by treatment group with descriptive statistics based 
on the ITT / mITT / efficacy -evaluable population. 95% CI of the estimates will be provided 
where appropriate. Treatme nt difference along with 95% CI will also be reported for Part 2 of 
the study. Subgroup analysis by stratification factors, i.e. age (<60 year  vs. ≥60 years)  and use 
of remdesivir (yes vs. no)  might be performed where data permits.   
For the efficacy endpoint s in Part 2, the primary endpoint will be analyzed using the exact 
method. Difference between two arms will be tested by a stratified Cochran –Mantel –Haenszel 
test (CMH) test  using  the stratification factors at randomization . Recovery rate by Day 14, 
recovery rate by Day 30, and a ll-cause mortality rate will be analyzed similarly. Time to 
recovery among subjects alive by Day 30 will be analyzed  by a stratified log -rank test  for p -
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  69  
 value , and the HR ratio between two arms will be estimated by a stratif ied Cox proportional 
hazard model  using  the stratification factors at randomization . For t he phase 2 portion the 
primary analysis will be based on the ITT population. For t he phase 3 portion the primary 
analysis will be based on the mITT population, and sensititivy analyses will be conducted 
based on the ITT population.  
For the Part 2 phase 3 portion,  multiplicity will be adjusted by a gatekeep ing procedure . If the 
null hypothesis  for the primary endpoint is rejected , then t he key secondary endpoints wil l be 
tested in the order of:  proportion of recovered subjects by Day 14 , proportion of recovered 
subjects by Day 30, and all -cause mortality rate by Day 30 .  
 
The primary clinical question of interest for the primary objective is  whether there is a  
differe nce in  proportion of subjects who are alive and  free of  mechanical ventilation  after 30 
days comparing TJ003234 10 mg/kg versus  placebo  in COVID -19 subjects who  have low 
blood oxygen or requires high flow oxygen  regardless of initiation of additional medication or 
change in background medication ( remdesivir and/or steroids ). The clinical question of interest 
for the secondary objectives are similar, which is whether there is a difference in proportion of 
subjects  who will recover after 14 or 30 days comparing TJ003234 10 mg/kg versus  placebo  in 
iCOVID -19 subjects who have low blood oxygen or requires high flow oxygen  regardless of 
initiation of additional medication or change in background medication ( remdesivir and/or 
steroids ). 
 
The estimand is described by the following attributes:  
 Population: severe ho spitalized COVID -19 subjects  who require non mv  oxygen supply  
at baseline .  
 Endpoint: proportion of subjects  who are no n-mechanical ventilated  at baseline by Day 
30.  
 Treatment condition: TJ003234 10 mg/kg and placebo  with or without background 
medication ( remdesivir and/or steroids ). 
 Intercurrent events and strategies: The intercurrent events “change in background 
medication ( remdesivir and/or steroids )” are addressed by the treatment condition of 
interest attribute following the treatment policy strategy. Other relevant intercurrent 
events are not anticipated at this point in time.  
 Population -level summary: difference in proportion s between treatment conditio ns 
 
The trial will be considered as successful if the primary endpoint in Phase 3 portion  shows a 
statistically significant improvement in the treatment arm and , as a safety measurement, the  all-
cause mortality rate in the treatment arm is numerically not higher than that in the control 
arm.Sensitivity analyses and subgroup analysis will be performed to investigate the robustness 
of the primary efficacy outcome. Details will be provided in the statistical analysis plan (SAP).  
 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  70  
 9.6. Independent Data Monitori ng Committee   
The Independent Data Monitoring Committee ( IDMC) is responsible for monitoring safety . The 
IDMC  will be made up entirely of members  external to I -Mab. The IDMC  charter will contain 
membership information and a further delineation of responsibilities.  
The IDMC may recommend continuing enrollment in one dose arm or to terminate the study 
for accumulated safety evaluations. The IDMC will provide a recommendation that is made 
without known bias. I -Mab staff involved in the conduct of the study will be kept blinded to 
before a portion of the study is completed, and the members of the IDMC will not have 
involvement with the conduct of the study.  
 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  71  
 10. Regulatory H uman Subject Protection and Regulatory Oversight  
10.1. Regulatory and Ethical Considerations  
This study will be conducted in accordance with the protocol and with the following:  
 Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations  of Medical 
Sciences (CIOMS) International Ethical Guidelines.  
 Applicable International Conference on Harmonisation (ICH) Good Clinical Practice 
(GCP) Guidelines.  
 Applicable laws and regulations.  
The protocol, protocol amendments, Informed Consent Form (IC F), Investigator ’s Brochure, 
and other relevant documents (e .g., advertisements) must be submitted to an Institutional 
Review Board (IRB) by the Investigator and reviewed and approved by the IRB before the 
study is initiated.  
Any amendments to the protoco l will require IRB and regulatory authority (as locally required) 
approval before implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study subjects.  
The Investigator will be responsible for  the following:  
 Providing written summaries of the status of the study to the IRB annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB.  
 Notifying the IRB of SAEs or other significant safety findin gs as required by IRB 
procedures.  
 Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, the IRB, 
European regulation 536/2014 for clinical studies (if applicable),  and all other 
applicable local regulations.  
10.2. Informed Consent Processes and Documentation  
In obtaining and documenting informed consent, the Investigator must comply with applicable 
regulatory requirements (e.g., 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part  56) and should 
adhere to ICH GCP. Prior to the beginning of the trial, the Investigator should have the IRB ’s 
written approval for the protocol and the written ICF and any other written information to be 
provided to the participants. Participants will be asked to read and review the IRB -approved ICF 
and other written information.  The ICF should include a detailed description of study 
procedures, risk and benefits, directions, participant ’s rights, compensation (if applicable), and 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  72  
 contact of Human Subject  Protection Services.  Additionally, the Investigator will explain the 
research study to the participant in terms suited to the participant ’s comprehension and answer 
any questions that may arise. The Investigator should explain their rights as research pa rticipants, 
study procedures, risk and benefits, and anticipated adverse effects.  Participants will have the 
opportunity to carefully review the written consent form and ask questions prior to signing. ICF 
should be signed prior to any interventions are p erformed for the study. Participants must be 
informed that participation is voluntary and that they may withdraw from the study at any time, 
without prejudice. Participant will be given a copy of the signed consent form and the original 
consent form will b e kept as a permanent record.  
10.3. Confidentiality   
Participant confidentiality and privacy is strictly held in trust by the participating Investigator(s), 
their staff, and the Sponsor(s) and their interventions. This confidentiality is extended to cover 
testing of biological samples and genetic tests in ad dition to the clinical information relating to 
participants. Therefore, the study protocol, documentation, data, and all other information 
generated will be held in strict confidence. No information concerning the study or the data will 
be released to any unauthorized third party without prior written approval of the Sponsor.  
All research activities will be conducted in as private a setting as possible.  
The study monitor, other authorized representatives of the Sponsor, representatives of the IRB, 
regulatory agencies, or pharmaceutical company supplying study product may inspect all 
documents and records required to be maintained by the Investigator, including but not limited 
to, medical records (office, clinic, or hospital) and pharmacy records for  the participants in this 
study. The clinical study site will permit access to such records.  
The study participant ’s contact information will be securely stored at each clinical site for 
internal use during the study. At the end of the study, all records w ill continue to be kept in a 
secure location for as long a period as dictated by the reviewing IRB, institutional policies, or 
Sponsor requirements.  
Research data, which is for purposes of statistical analysis and scientific reporting, will be 
transmitted to and stored at the data management group at the designated CRO. This will not 
include the participant ’s contact or identifying information. Rather, individual participants and 
their research data will be identified by a unique study identification number . The study data 
entry and study management systems used by clinical sites and by CRO staff will be secured, 
and password protected. At the end of the study, all study databases will be de -identified and 
archived at the CRO or Sponsor until further data in tegration with future studies of TJ003234.  
10.4. Conf lict of Interest   
The independence of this study from any actual or perceived influence, such as by the 
pharmaceutical industry, is critical.  Therefore, any actual conflict of interest of persons who 
have a r ole in the design, conduct, analysis, publication, or any aspect of this trial will be 
disclosed and managed. Furthermore, persons who have a perceived conflict of interest will be 
required to have such conflicts managed in a way that is appropriate to the ir participation in the 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  73  
 design and conduct of this trial.  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  74
  
 11. Quality Control and Quality Assurance   
Sponsor or designee will conduct periodic monitoring visits to ensure that the protocol and 
current Good Clinical Practices within standard  operating procedures are being followed. 
The monitors may review source documents to confirm that the data recorded on CRFs are 
accurate. The Investigator and institution will allow the Sponsor ’s medical monitors or its 
agents and appropriate regulatory a uthorities direct access to source documents to perform 
this verification. Accuracy will be checked by performing source data verification that is a 
direct comparison of the entries made onto the CRFs against the appropriate source 
documentation. Any resul ting discrepancies will be reviewed with the Investigator and/or 
his/her staff. Any necessary corrections will be made directly to the electronic CRFs or via 
queries by the Investigator and/or his/her staff. Monitoring procedures require that informed 
consents, adherence to inclusion/exclusion criteria, and documentation of SAEs and their 
proper recording be verified. Additional monitoring activities may be outlined in a study 
specific monitoring plan.  
12. Confidentiality and Publication of Test Results  
All information about this trial (including but not limited to the following documents: 
protocols, investigator ’s brochure) must be kept strictly confidential. Investigators shall be 
aware that the scientific or medical information derived from this trial may be of commercial 
value to the sponsor. Investigators should keep the information and data related to the trial 
confidential. If Investigators are intended to publicly release information or conclusions 
obtained from the trial, they shall consult with the s ponsor in advance and obtain the written 
consent of the sponsor. In order to protect rights and interest, the sponsor may require 
investigators not to publish information about the trial until the trial product is approved for 
marketing.   
The sponsor has the right to publish or release information or data related to the trial, or 
report them to the regulatory authorities .  
  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  75
  
 13. References   
Avci, A .B., Feist, E. and Burmester, G.R. (2016). Targeting GM -CSF in Rheumatoid 
Arthritis . Clin Exp Rheumatol , 34 (4 Suppl 98):39 –44. 
Beigel , J.H. , Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S., Kalil, A.C.,… 
Lane, H.C. for the ACTT -1 Study Group Members  (2020) . Remdesivir for the Treatment 
of Covid -19 — Preliminary Report . New England Journal of Medici ne, Published Online 
2020 May 22;  NEJMoa2007764. doi: 10.1056/NEJMoa2007764.  
Broughton, S. E., Nero, T. L., Dhagat, U., Kan, W. L., Hercus, T. R., Tvorogov, D., … 
Parker, M. W. (2015). The βc receptor family – Structural insights and their functional 
implicati ons. Cytokine , 74(2), 247 –258. doi: 10.1016/j.cyto.2015.02.005  
Burmester, G. R., Mcinnes, I. B., Kremer, J., Miranda, P., Korkosz, M., Vencovsky, J., … 
Weinblatt, M. E. (2017). A randomised phase IIb study of mavrilimumab, a novel GM –
CSF receptor alpha mon oclonal antibody, in the treatment of rheumatoid arthritis.  Annals 
of the Rheumatic Diseases , 76(6), 1020 –1030. doi: 10.1136/annrheumdis -2016 -210624  
Channappanavar, Rudragouda, and Stanley Perlman. “Pathogenic Human Coronavirus 
Infections: Causes and Cons equences of Cytokine Storm and 
Immunopathology. ” Seminars in Immunopathology , vol. 39, no. 5, Feb. 2017, pp. 529–
539., doi:10.1007/s00281 -017-0629 -x. 
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y ., … Zhang, L. (2020). 
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus 
pneumonia in Wuhan, China: a descriptive study.  The Lancet , 395(10223), 507 –513. doi: 
10.1016/s0140 -6736(20)30211 -7 
Chinese Clinical Trial Registry. (n.d.). Retrieved from 
http://www.chictr.org.cn/showproj.aspx?proj=49409  
De Luca, G., Cavalli , C., Campochiaro , C., Della -Torre , E., Angelillo , P., Tomelleri , A.,… 
Dagna . L. (2020). GM-CSF blockade with mavrilimumab  in severe COVID -19 pneumonia 
and systemic hyperinflammation: a single -centre, prospective cohort study. Lancet 
Rheumatol , Published Online June 16, 2020 doi: https://doi.org/10.1016/S2665 -
9913(20)30170 -3 
FDA Guidance for Industry. Estimating the Maximum S afe Starting Dose in Initial Clinical 
Trials for Therapeutics in Adult Healthy V olunteers, July 2005  
Gilead. Press Releases. https://www.gilead.com/news -and-press/press -room/press -
releases. Accessed March 8, 2020.  
Goldman, J.D., Lye, D.C.B., Hui, D. S., Marks, K.M., Bruno, R., Montejano, R, … and 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  76
  
 Subramanian, A. (2020). Remdesivir for 5 or 10 Days in Patients  with Severe Covid -19 
New England Journal of Medicine , Published Online  May 27, 2020,  DOI: 
10.1056/NEJMoa2015301  
Guan, W. -J., Ni, Z. -Y ., Hu, Y ., Liang, W. -H., Ou, C. -Q., He, J. -X., … Zhong, N. -S. (2020). 
Clinical characteristics of 2019 novel coronavirus infection in China. doi: 
10.1101/2020.02.06.20020974  
Gust J, Finney O, Li D, Brakke HM, Hicks RM et al. (2019). Gl ial injury in neurotoxicity 
after pediatric CD19 -directed chimeric antigen receptor T cell therapy. Ann Neurol . 
86(1):42 -54. 
Hamilton, J. A. (1980). Macrophage stimulation and the inflammatory response to 
asbestos.  Environmental Health Perspectives , 34, 69–74. doi: 10.1289/ehp.803469  
Hansen, G., Hercus, T., Woodcock, J., Mcclure, B., Stomski, F., Xu, Y ., … Parker, M. 
(2008). Structure of the GM -CSF Receptor Complex. doi: 10.2210/pdb3cxe/pdb  
Hercus, T. R., Kan, W. L. T., Broughton, S. E., Tvorogov, D., Ramsh aw, H. S., Sandow, J. 
J., … Lopez, A. F. (2017). Role of the β Common (βc) Family of Cytokines in Health and 
Disease.  Cold Spring Harbor Perspectives in Biology , 10(6). doi: 
10.1101/cshperspect.a028514  
Huang, C., Wang, Y ., Li, X., Ren, L., Zhao, J., Hu, Y . , … Cao, B. (2020). Clinical features 
of patients infected with 2019 novel coronavirus in Wuhan, China.  The 
Lancet , 395(10223), 497 –506. doi: 10.1016/s0140 -6736(20)30183 -5 
Huizinga, T. W. J., Batalov, A., Stoilov, R., Lloyd, E., Wagner, T., Saurigny, D., … 
Esfandiari, E. (2017). Phase 1b randomized, double -blind study of namilumab, an anti -
granulocyte macrophage colony -stimulating factor monoclonal antibody, in mild -to-
moderate rheumatoid arthritis. Arthritis Research & Therapy, 19 (1). doi: 10.1186/s13075 -
017-1267 -3 
I-Mab Biopharma. TJ003234RAR101 Clinical Study Report. (Version 1.0). 03 January 
2020.  
I-Mab Biopharma. TJ003234 – Investigator’s Brochure. (Version 3.0). XX March 2020.  
 
Jenkins, B. J., Blake, T. J., & Gonda, T. J. (1998). Saturation Mutagenesis of the β Subunit 
of the Human Granulocyte -Macrophage Colony -Stimulating Factor Receptor Shows 
Clustering of Constitutive Mutations, Activation of ERK MAP Kinase and STAT Pathways, 
and Differential β Subunit Tyrosine Phosphorylation.  Blood , 92(6), 1989 –2002. doi: 
10.1182/blood.v92.6.1989.418k18_1989_2002  
Lang , F.M. , Lee , K. M .-C., Teijaro , J.R. , Becher , B., & Hamilton J. A. (2020). GM-CSF-
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  77
  
 based treatments in COVID -19: reconciling opposing therapeutic approaches . Nat Rev 
Immunol . 2020 Jun 23; 1-8. doi: 10.1038/s41577 -020-0357 -7. 
Le, R. Q., Li, L., Yuan, W., Shord, S. S., Nie, L., Habtemariam, B. A., … Przepiorka, D. 
(2018). Tocilizumab for Treatment of Severe or Life -Threatening Chimeric Antigen 
Receptor T Cell -Induced Cytokine Release S yndrome —FDA Approval Summary.  Biology 
of Blood and Marrow Transplantation , 24(3). doi: 10.1016/j.bbmt.2017.12.104  
Ryan, P. C., Sleeman, M. A., Rebelatto, M., Wang, B., Lu, H., Chen, X., … Dixit, R. (2014). 
Nonclinical safety of mavrilimumab, an anti -GMCSF receptor alpha monoclonal antibody, 
in cynomolgus monkeys: Relevance for human safety.  Toxicology and Applied 
Pharmacology , 279(2), 230 –239. doi: 10.1016/j.taap.2014.06.002  
Sachdeva, Mohit, et al. “Granulocyte –Macrophage Colony -Stimulating Factor 
Inactivat ion in CAR T -Cells Prevents Monocyte -Dependent Release of Key Cytokine 
Release Syndrome Mediators. ” Journal of Biological Chemistry , vol. 294, no. 14, 2019, 
pp. 5430 –5437., doi:10.1074/jbc.ac119.007558.  
Sato, N., Sakamaki, K., Terada, N., Arai, K., & Miyaj ima, A. (1993). Signal transduction 
by the high -affinity GM -CSF receptor: two distinct cytoplasmic regions of the common 
beta subunit responsible for different signaling.  The EMBO Journal , 12(11), 4181 –4189. 
doi: 10.1002/j.1460 -2075.1993.tb06102.x  
Schulert , Grant S., et al. “Systemic Juvenile Idiopathic Arthritis –Associated Lung Disease: 
Characterization and Risk Factors. ” Arthritis & Rheumatology , vol. 71, no. 11, 2019, pp. 
1943 –1954., doi:10.1002/art.41073.  
Sterner, RM, et al. GM -CSF inhibition reduces cy tokine release syndrome and 
neuroinflammation but enhances CAR -T cell function in xenografts.  Blood . 
2019;133(7):697 -709 
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., … Peng, Z. (2020). Clinical 
Characteristics of 138 Hospitalized Patients With 20 19 Novel Coronavirus –Infected 
Pneumonia in Wuhan, China.  Jama . doi: 10.1001/jama.2020.1585  
Xu Z, Shi L, Wang Y , Zhang J, Huang J, et al. (2020). Pathological findings of COVID -19 
associated with acute respiratory distress syndrome.  Lancet Respir Med . doi: 
10.1016/S2213 -2600(20)30076 -X. 
Zhou, Yonggang, et al. “Aberrant Pathogenic GM -CSF T Cells and Inflammatory CD14 
CD16 Monocytes in Severe Pulmonary Syndrome Patients of a New Coronavirus. ” 2020, 
doi:10.1101/2020.02.12.945576.  
 
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  78
  
 14. Appendic es   
14.1. Appendix 1: Contraceptive requirements  
Definition of women of childbearing potential :  
Non-fertile women are defined as post -menopausal women and pre -menopausal women 
who have undergone surgical sterilization. Postmenopausal is defined as menopause ≥ 12 
months without alternative medical measures. Follicle Stimulating Hormone (FSH) test 
should be  performed for subjects  who are not sure of their menopausal status , and if FSH>40 
MlU/mL, it can be co nfirmed as menopause. Sterilization operations include bilateral 
fallopian tube ligation or bilateral ovariectomy or hysterectomy.  
Women of childbearing age are defined as those who are anatomically and physiologically 
able to get pregnant.   
Contraceptive  requirements  
Women of childbearing potential must  have a negative pregnancy test during the screening 
period. If of childbearing potential, women must agree to one of the  following methods of 
contraception beginning at screening and continuing for a peri od of 4 months after the final 
dose of IP:  
 Hormonal contraception (e.g., oral contraceptive, contraceptive implant, or injectable 
hormonal contraceptive)  
 Double -barrier birth control (e.g., condom plus intrauterine device, diaphragm plus 
spermicide or con dom plus spermicide)  
 Maintenance of a monogamous relationship with a male partner who has been 
surgically sterilized by vasectomy  
 Abstinence  
Male subjects who are sexually active must agree to use a double -barrier method of 
contraception (condom with spermicide) from the first dose of randomized study drug until 
4 months  after their last dose and must not donate sperm during their study partici pation 
period.  
  
14.2. Appendix 2: Cardiac Function Grading of NYHA  
Grade I: A patient has a heart disease, but his/her daily activity is not limited. General 
physical activity will not cause excessive fatigue, palpitations, asthma or angina.  
Grade II: a patient with heart disease has slightly limited physical activity. He/she has no 
conscious symptoms at rest, and general physical activity may cause excessive fatigue, 
palpitations, asthma or angina.  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  79
  
 Grade III: a patient with heart disease has obviously limited physical activity. He/she has no 
symptoms at rest, but physical activity lower than normal level may cause excessive fatigue, 
palpitations, asthma or angina.  
Grade IV: a patient with heart disease cannot engage in any physical activity, a nd heart 
failure symptoms also occur during rest, which worsens after physical activities.  
 
14.3. Appendix 3: Sequential Organ Failure Assessment Score  
System  Test Item  0 1 2 3 4 Score  
Respiratory 
system  PaO2/FiO2 , 
mmHg  (kPa)  >400  
(>53.33)  301-400 
(≤53.33  
and >40)   201-300 
(≤40 
and >26.6
7) 101-200 
(≤26.67 ) ≤100  
(<13.33
)  
Respiratory 
support 
(yes/no)     Yes  Yes  
Coagulation 
system  Platelets , 109/L  >150 101-150 51-100 21-50 <21  
Liver  Bilirubin , 
mg/dL  
(umol/L)  <1.2 
(<20) 1.2-1.9 
(20-32) 2.0-5.9 
(33-101) 6.0-11.9 
(102-
204) >12.0 
(>204)  
Circulatory 
system  Mean arterial 
pressure 
(mmHg)  ≥70 <70     
Dopamine 
dose 
(ug/kg/min)    ≤5 or  >5 or  >15 or  
Adrenaline 
dose 
(ug/kg/min)     ≤0.1 or >0.1 or  
Norepinephrin
e dose 
(ug/kg/min)     ≤0.1 >0.1 
Dobutamine 
(yes / no)    Yes    
Nervous 
system  GCS score  15 13-14 10-12 6-9 <6  
Kidneys  Creatinine , 
mg/dL  
(umol/L)  <1.2 
(<110 ) 1.2-1.9 
(110-
170) 2.0-3.4 
(171-299) 3.5-4.9 
(300-
440) >5.0 
(>440 )  
24-hour urine 
output 
(ml/24h)     201-500 <200  
Remarks:  1. The worst daily value should be taken for daily assessment;  
2. The higher the score, the worse the prognosis.  
Version 90   Version Date:  23 September 2021  
  
I-Mab Biopharma Co., Ltd.  CONFIDENTIAL  80
  
 3. For the respiratory system score, to receive a score of 3 or 4 points, the patient 
needs to be mechanically ventilated. If the pat ient has a PaO2/FiO2 value of ≤40 
kPa and the patient is not on mechanical ventilation, the score will be 2, regardless 
if the value is lower than 26.67.   
 
14.4. Appendix 4: Inhaled cor ticosteroid dose guidance  
Adapted from Global Strategy for Asthma Management and Prevention – GINA 2019.  
This is not a table of equivalence, but of estimated clinical comparability based on available 
studies and product information.  
Doses are in mcg. CFC: chlorofluorocarbon propellant. DPI: dry powder inhaler. HF A: 
hydrofluoroalkane propellant.  
 
Inhaled corticosteroid  Adults and adolescents  
Low  Medium  High  
Beclometasone dipro pionate (CFC)  200-500 >500 -1000  >1000  
Beclometasone dipropionat  100-200 >200 -400 >400  
Budesonide (DPI)  200-400 >200 -400 >400  
Ciclesonide (HFA)  80-160 >160 -320 >320  
Fluticasone furoate (DPI)  100 n.a. 200 
Fluticasone priopionate (DPI)  100-250 >250 -500 >500  
Fluticasone priopionate (HFA)  100-250 >250 -500 >500  
Mometasone furoate  110-220 >220 -440 >440  
Triamcinolone acetonide  400-1000  >1000 -2000  >2000  
 
 
Certificate Of Completion
Envelope Id: 00A93AB15C5E45AE8208C5DCDBA11A37 Status: Completed
Subject: Please DocuSign: TJ003234COV201_Protocol_Version 9.0_FINAL_23Sep2021.docx
Source Envelope: 
Document Pages: 80 Signatures: 1 Envelope Originator: 
Certificate Pages: 4 Initials: 0 Andria White
AutoNav: Enabled
EnvelopeId Stamping: Disabled
Time Zone: (UTC+08:00) Beijing, Chongqing, Hong Kong, UrumqiAndria.White@i-mabbiopharma.us
IP Address: 24.47.35.145   
Record Tracking
Status: Original
             9/24/2021 3:38:54 AMHolder: Andria White
             Andria.White@i-mabbiopharma.usLocation: DocuSign
Signer Events Signature Timestamp
Claire Xu
claire.xu@i-mabbiopharma.com
US Site Head
Security Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signature ID: 
694B2B1E-EED8-462B-8E8C-4CD8F1AD4794
Using IP Address: 71.246.231.35
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this documentSent: 9/24/2021 3:39:58 AM
Viewed: 9/24/2021 3:48:18 AM 
Signed: 9/24/2021 3:48:32 AM
Electronic Record and Signature Disclosure: 
      Accepted: 9/24/2021 3:48:18 AM
      ID: 1ddbbfe1-06b7-494b-ba6f-d5cffbdcc3c2
In Person Signer Events Signature Timestamp
Editor Delivery Events Status Timestamp
Agent Delivery Events Status Timestamp
Intermediary Delivery Events Status Timestamp
Certified Delivery Events Status Timestamp
Carbon Copy Events Status Timestamp
Witness Events Signature Timestamp
Notary Events Signature Timestamp
Envelope Summary Events Status Timestamps
Envelope Sent Hashed/Encrypted 9/24/2021 3:39:58 AM
Certified Delivered Security Checked 9/24/2021 3:48:18 AM
Signing Complete Security Checked 9/24/2021 3:48:32 AM
Completed Security Checked 9/24/2021 3:48:32 AM
Payment Events Status Timestamps
Electronic Record and Signature Disclosure
ELECTRONIC RECORD AND SIGNATURE DISCLOSURE   
From time to time, Ingram Micro (China) Limited OBO Master Concept OBO I -MAB 
Biopharma Co Ltd (we, us or Company) may be required by law to provide to you certain 
written notices or disclosures. Described below are the terms and conditions for providing to  you 
such notices and disclosures electronically through the DocuSign system. Please read the 
information below carefully and thoroughly, and if you can access this information electronically 
to your satisfaction and agree to this Electronic Record and Sig nature Disclosure (ERSD), please 
confirm your agreement by selecting the check -box next to ‘I agree to use electronic records and 
signatures’ before clicking ‘CONTINUE’ within the DocuSign system.  
 
Getting paper copies   
At any time, you may request from us  a paper copy of any record provided or made available 
electronically to you by us. You will have the ability to download and print documents we send 
to you through the DocuSign system during and immediately after the signing session and, if you 
elect to c reate a DocuSign account, you may access the documents for a limited period of time 
(usually 30 days) after such documents are first sent to you. After such time, if you wish for us to 
send you paper copies of any such documents from our office to you, you  will be charged a 
$0.00  per-page fee. You may request delivery of such paper copies from us by following the 
procedure described below.  
 
Withdrawing your consent   
If you decide to receive notices and disclosures from us electronically, you may at any time  
change your mind and tell us that thereafter you want to receive required notices and disclosures 
only in paper format. How you must inform us of your decision to receive future notices and 
disclosure in paper format and withdraw your consent to receive n otices and disclosures 
electronically is described below.  
 
Consequences of changing your mind   
If you elect to receive required notices and disclosures only in paper format, it will slow the 
speed at which we can complete certain steps in transactions with  you and delivering services to 
you because we will need first to send the required notices or disclosures to you in paper format, 
and then wait until we receive back from you your acknowledgment of your receipt of such 
paper notices or disclosures. Furthe r, you will no longer be able to use the DocuSign system to 
receive required notices and consents electronically from us or to sign electronically documents 
from us.  
 
All notices and disclosures will be sent to you electronically   
Electronic Record and Signature Disclosure created on: 6/21/2019 10:02:25 AM
Parties agreed to: Claire Xu
Unless you tell us otherw ise in accordance with the procedures described herein, we will provide 
electronically to you through the DocuSign system all required notices, disclosures, 
authorizations, acknowledgements, and other documents that are required to be provided or made 
available to you during the course of our relationship with you. To reduce the chance of you 
inadvertently not receiving any notice or disclosure, we prefer to provide all of the required 
notices and disclosures to you by the same method and to the same addres s that you have given 
us. Thus, you can receive all the disclosures and notices electronically or in paper format through 
the paper mail delivery system. If you do not agree with this process, please let us know as 
described below. Please also see the para graph immediately above that describes the 
consequences of your electing not to receive delivery of the notices and disclosures 
electronically from us.  
 
How to contact Ingram Micro (China) Limited OBO Master Concept OBO I -MAB 
Biopharma Co Ltd:   
You may con tact us to let us know of your changes as to how we may contact you electronically, 
to request paper copies of certain information from us, and to withdraw your prior consent to 
receive notices and disclosures electronically as follows:  
To contact us by em ail send messages to: wink.lv@i -mabbiopharma.com  
 
To advise Ingram Micro (China) Limited OBO Master Concept OBO I -MAB Biopharma 
Co Ltd of your new email address   
To let us know of a change in your email address where we should send notices and disclosures  
electronically to you, you must send an email message to us at  wink.lv@i -mabbiopharma.com 
and in the body of such request you must state: your previous email address, your new email 
address.  We do not require any other information from you to change your  email address.   
If you created a DocuSign account, you may update it with your new email address through your 
account preferences.  
 
To request paper copies from Ingram Micro (China) Limited OBO Master Concept OBO 
I-MAB Biopharma Co Ltd   
To request delive ry from us of paper copies of the notices and disclosures previously provided 
by us to you electronically, you must send us an email to  wink.lv@i -mabbiopharma.com  and in 
the body of such request you must state your email address, full name, mailing address , and 
telephone number.  We will bill you for any fees at that time, if any.  
 
To withdraw your consent with Ingram Micro (China) Limited OBO Master Concept OBO 
I-MAB Biopharma Co Ltd   
To inform us that you no longer wish to receive future notices and disclo sures in electronic 
format you may:  
i. decline to sign a document from within your signing session, and on the subsequent page, 
select the check -box indicating you wish to withdraw your consent, or you may;  
ii. send us an email to  wink.lv@i -mabbiopharma.co m and in the body of such request you must 
state your email, full name, mailing address, and telephone number.  We do not need any other 
information from you to withdraw consent..   The consequences of your withdrawing consent for 
online documents will be th at transactions may take a longer time to process..  
 
Required hardware and software   
The minimum system requirements for using the DocuSign system may change over time. The 
current system requirements are found here: https://support.docusign.com/guides/signer -guide -
signing -system -requirements .  
 
Acknowledging your access and consent to receive and sign documents electronically   
To confirm to us that you can access this information electronically, which will be similar to 
other electronic notices and disclosures that we will provide to you, please confirm that you have 
read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for 
your future reference and access; or (ii) that you are able to email this ERSD to an email address 
where you will be able to print on paper or save it for your future reference and access. Further, 
if you consent to receiving notices and disclosur es exclusively in electronic format as described 
herein, then select the check -box next to ‘I agree to use electronic records and signatures’ before 
clicking ‘CONTINUE’ within the DocuSign system.  
By selecting the check -box next to ‘I agree to use electron ic records and signatures’, you confirm 
that: 
 You can access and read this Electronic Record and Signature Disclosure; and  
 You can print on paper this Electronic Record and Signature Disclosure, or save or send 
this Electronic Record and Disclosure to a location where you can print it, for future 
reference and access; and  
 Until or unless you notify  Ingram Micro (China) Limited  OBO Master Concept OBO I -
MAB Biopharma Co Ltd as described above, you consent to receive exclusively through 
electronic means all notices, disclosures, authorizations, acknowledgements, and other 
documents that are required to be provided or made availabl e to you by  Ingram Micro 
(China) Limited OBO Master Concept OBO I -MAB Biopharma Co Ltd during the course 
of your relationship with Ingram Micro (China) Limited OBO Master Concept OBO I -
MAB Biopharma Co Ltd.  